2014N210004_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200952
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A Repeat -dose Study  in Subjects with Ty pe [ADDRESS_484900]
Comp ound Number: [COMPANY_004]716155
Development Phase: III
Effective Date: 26-MAY -2016
Protocol Amendment Number:  02
Author (s):  
Copy right [ADDRESS_484901] is “lost to follow -up” or withdraws 
consent.
Minor updates to b enefit risk table 
Clarification in inclusion criteria that those subjects on a stable dose of metforim must be 
receiving metformin as monotherapy .
Exclusion criteria relating to use of dipeptidy l peptida se-IV inhibitors updated to include 
GLP [ADDRESS_484902] of missing data on primary  anal ysis, and sensitivity  anal ysis.
2014N210004_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 200952
3Minor ty pographical errors
[COMPANY_003]
[COMPANY_003]
2014N210004_02 CONFIDENTIA L
200952
5MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171] : 
Role Name [CONTACT_387071] -hours 
Phone/Cell/
Pager NumberFax 
NumberSite 
Address
Primary Medical 
Monitor  
MD
[COMPANY_003] 
Pharmacovigilance24-hour Safety 
Hotline
Email – N/A24-hour Safety 
HotlineN/A
Secondary 
Medical Monitor MD
[COMPANY_003] 
Pharmacovigilance24-hour Safety 
Hotline
Email – N/A24-hour Safety 
HotlineN/A
SAE Coordinator [COMPANY_003] 
Pharmacovigilance
North America24-hour Safety 
Hotline24-hour Safety 
HotlineN/A
FAX number for 
SAE reporting
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_484903] research organization for this study
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_131980].   
Regulatory  Agency  Identify ing Number(s):  US IND [ADDRESS_484904] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782]
2014N210004_02 CONFIDENTIA L
200952
7TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 200952 ...................................................... 10
2.INTRODUCTION ................................
.................................................................... 13
2.1. Study Rationale .......................................................................................... 13
2.2. Brief Background ........................................................................................ 13
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 15
4.STUDY DESIGN .................................................................................................... 15
4.1. Overall Design ............................................................................................ 15
4.2. Treatment Arms and Duration ..................................................................... 16
4.3. Type and Number of Subjects ..................................................................... 17
4.4. Design Justification ..................................................................................... 17
4.5. Dose Justification ........................................................................................ 18
4.6. Benefit:Risk Assessment ............................................................................ 18
4.6.1. Risk Assessment ......................................................................... 19
4.6.2. Benefit Assessment ..................................................................... 27
4.6.3. Overall Benefit: Risk Conclusion .................................................. [ADDRESS_484905] AWAL CRITERIA ............. 28
5.1. Inclusion Criteria ......................................................................................... 28
5.2. Exclusion Criteria ........................................................................................ 29
5.3. Screening/Baseline/Run -in Failures ............................................................ 32
5.4. Hyperglycemia Rescue ............................................................................... 32
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... [ADDRESS_484906] ................. 33
[IP_ADDRESS]. Procedures for Subject Follow -up Following 
Discontinuation of Investigational Product .................. 34
5.5.2. Subjects W ho Fail to Attend Clinic Visits ...................................... 34
5.5.3. Withdrawal from Study ................................................................ .35
5.5.4. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 35
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_484907] and Other Study Treatment .................................... 37
6.2. Treatment Assignment ................................................................................ 40
6.3. Planned Dose Adjustments ......................................................................... 40
6.4. Blinding ....................................................................................................... 40
6.5. Packaging and Labeling .............................................................................. 41
6.6. Preparation/Handling/Storage/A ccountability .............................................. 41
6.7. Compliance with Study Treatment Administration ....................................... 42
6.8. Treatment of Study Treatment Overdose .................................................... 42
6.9. Treatment after the End of the Study .......................................................... 42
6.10. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 43
6.10.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 43
6.10.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 43
2014N210004_02 CONFIDENTIA L
200952
87.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 45
7.1. Time and Events ......................................................................................... 46
7.2. Screening and Critical Baseline Assessments ............................................ 50
7.3. Efficacy ....................................................................................................... 50
7.4. Safety ......................................................................................................... 50
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 50
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 50
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 51
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 51
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 51
[IP_ADDRESS]. AEs of Special Interest ............................................... 52
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 52
7.4.2. Pregnancy ................................................................................... 53
7.4.3. Physical Exams ........................................................................... 53
7.4.4. Vital Signs .................................................................................... 54
7.4.5. Electrocardiogram (ECG) ............................................................. 54
7.4.6. Clinical Safety Laboratory Assessments ...................................... 54
7.4.7. Estimated Glomerular Filtration Rate (eGFR) .............................. 57
7.4.8. Diabetic Dietary, Exercise, and Home Plasma Glucose 
Monitoring Advice ........................................................................ 57
7.4.9. Hypoglycemic Events ................................................................... 57
7.5. Tracking of Albiglutide Lyophilized DCC Pen Injector and Liquid 
Auto-injector Fail ures and User Errors ........................................................ 58
7.6. Pharmacokinetics ....................................................................................... 58
7.6.1. Blood Sample Collection .............................................................. 58
7.6.2. Sample Analysis .......................................................................... 59
7.7. Immunogenicity ........................................................................................... 59
7.8. Genetics ..................................................................................................... 59
8.DATA MANAGEMENT ........................................................................................... 60
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .60
9.1. Hypotheses ................................................................................................ .60
9.2. Sample Size Considerations ....................................................................... 60
9.2.1. Sample Size Assumptions ........................................................... 60
9.2.2. Sample Size Sensitivity ................................................................ 61
9.2.3. Sample Size Re- estimation or Adjustment ................................... 61
9.3. Data Analysis Considerations ..................................................................... 62
9.3.1. Analysis Populations .................................................................... 62
9.3.2. Interim Analysis ........................................................................... 62
9.4. Key Elements of Analysis Plan ................................................................... 62
9.4.1. Primary Analyses ......................................................................... 62
9.4.2. Secondary Analyses .................................................................... 63
9.4.3. Other Analyses ............................................................................ 64
9.4.4. Supportive Analyses for Primary Endpoint ................................... 64
9.4.5. Missing Data ................................................................................ 65
[IP_ADDRESS]. Impact of Missing Data on Primary Endpoint .............. 65
[IP_ADDRESS]. Extent of Missing Primary Analysis Data .................... 65
[IP_ADDRESS]. Reasons for Withdrawal ............................................. 65
[IP_ADDRESS]. Handling of Missing Data ............................................ 65
2014N210004_02 CONFIDENTIA L
200952
910. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 67
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 67
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 67
10.3. Quality Control (Study Monitoring) .............................................................. 68
10.4. Quality Assurance ....................................................................................... 68
10.5. Study and Site Closure ............................................................................... 68
10.6. Records Retention ...................................................................................... 69
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Regi sters and Publication ................. 70
10.8. Review Committees .................................................................................... 70
11.REFERENCES ....................................................................................................... 71
12.APPENDICES ........................................................................................................ 72
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 72
12.2. Appendix 2: [COMPANY_004] Modified List of Highly Effective Methods for 
Avoiding Pregnancy in Females of Reproductive Potential (FRP) ............... 75
12.3. Appendix 3: Liver Safety Required Actions and Follow up
Assessments .............................................................................................. 76
12.4. Appendix 4: Genetic Research ................................................................... 80
12.5. Appendix 5: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 83
12.5.1. Definition of Adverse Events ........................................................ 83
12.5.2. Definition of Serious Adverse Events ........................................... 84
12.5.3. Definition of Cardiovascular Events ............................................. 85
12.5.4. Recording of AEs and SAEs ........................................................ 86
12.5.5. Evaluating AEs and SAEs ............................................................ 86
12.5.6. Reporting of SAEs to [COMPANY_004] ........................................................... 88
12.6. Appendix 6: Collection of Pregnancy Information ........................................ 89
12.7. Appendix 7: Immunogenicity Testing Algorithm ........................................... 90
12.8. Appendix 8: Country Specific Requirements ............................................... 92
12.9. Appendix 9: Protocol Amendment Changes ................................................ 93
2014N210004_02 CONFIDENTIA L
200952
101. PROTOC OL SYNOPSIS FOR STUD Y 200952
Rationale
Albiglutide is a novel analogue of glucagon -like peptide -1 (GLP -1) with a sufficiently  
long half -life to permit once a week injection. Albiglutide has been developed for the 
treatment of t ype 2 diabetes mellitus (T2DM ) as an adjunct to diet and exercise, as 
monotherap y, or in combination with existing therapi[INVESTIGATOR_387012] (FDA), the European Medicines Agency  (EMA) and other 
regulatory  agencies. 
Currently , lyophilized a lbiglutide and the diluent are provided in a dual chamber 
cartridge (DCC), single -dose pen injector, requiring reconstitution prior to use. A liquid 
formulation of albiglutide will enable the commercialization of a liquid product in a 
single dose, read y-to-use prefilled s yringe in an auto -injector. Study  201287, a healthy  
volunteer bioequivalence study  will be conducted as the first component of the 
comparability  assessment and the proposed study , Study  200952, will be conducted as the 
final component. This study  will compare the efficacy , safet y, tolerability and 
pharmacod ynamic (PD) response of the l yophilized DCC pen injector product to the 
liquid auto -injector product.  Specificall y, potential for immunogenicity (e.g. incidences 
of anti -drug antibodies [ ADA]) and injection site reactions (I SRs) will be evaluated.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To evaluate the efficacy of albiglutide liquid 
product as measured by [CONTACT_387047] (HbA 1c) change from baseline 
at Week 26.Change f rom baseline in HbA1c at Week 26
Secondary
To assess safety and tolerability of 
albiglutide specifically immunogenicity and 
ISRs.Adverse events (AEs) and serious AEs 
(SAEs), physical examinations, clinical 
laboratory evaluations, vital signs, and 12 -
lead electrocardiograms (ECGs).
Anti-albiglutide antibody production and 
rates of ISRs over time.
To evaluate the PD effect of albiglutide on 
fasting plasma glucose (FPG) change from 
baseline at Week 26.Change from baseline in FPG at Week 26
To assess the PD effect of albiglutide over 
timeChange from baseline in HbA1c over time
Change from baseline in FPG over time
To evaluate trough PK concentrations of 
albiglutide following repeat dosingTrough concentrations of albiglutide
2014N210004_02 CONFIDENTIA L
200952
11Overall Design
This is a pha se III, randomized, double -blind, multicenter, parallel -group, repeat -
dose, study  of [ADDRESS_484908] in subjects with T2DM failing to achieve optimal gl ycemic control on 
their current regimen of diet and exercise or stable dose of metformin .
At randomization, subjects will be stratified by [CONTACT_654] (<65 or ≥65 y ears of age), weight 
(<90 kg or ≥90kg), and backgr ound antidiabetic therap y (diet and exercise or stable 
dose of metformin).
Treatment A rms and Duration
This study  will comprise 3 study  periods: screening (2 weeks), treatment (26 weeks) 
and for those subjects not entering the extension study  a follow -up period (8 weeks).
Subjects will be randomized in a 1:1 ratio to either: 
Albiglutide active liquid auto- injector  + placebo ly ophilized DCC pen injector; 
or,
Albiglutide active l yophilized DCC pen injector + placebo liquid auto -injector.
Study  treatment wil l be administered once weekl y by [CONTACT_6567] (s.c.) injection in 
the abdomen, thigh, or upper arm.
Subjects will receive 30 mg of albiglutide for 4 weeks and will then be up -titrated to 
50 mg albiglutide for the remaining 22 weeks of the study. 
Type and Number of Subjects
The study  will recruit subjects with T2DM (>3 months since diagnosis) who are 
failing to achieve optimal gl ycemic control (HbA 1c7-10%) on their current regimen 
of diet and exercise or stable dose of metformin (maintained for approximate ly 8 
weeks prior to screening).
Approximately  300 subjects will be randomized. 
Analysis
Primary analyses:
HbA 1cchange from baseline at Week [ADDRESS_484909] model 
with repeated measures (MMRM) in the intent -to-treat (ITT) populati on.  MMRM will 
use all available data, including post -hypergl ycemia rescue data, and will include data 
from subj ects who discontinue treatment.   Imputation under the non -inferiority  null 
hypothesis for missing data will be incorporated. Non -inferiorit y testing will be 
performed at a one -sided alpha of 0.025 and non -inferiorit y margin of 0.4.
2014N210004_02 CONFIDENTIA L
200952
12Secondary analyses:
The evaluation of the safety  and tolerability  as assessed by  [CONTACT_387048] I SRs of 
albiglutide liquid drug product and the l yophilized drug pro duct will be provided by  
[CONTACT_387049], and the associated 95% CI . 
The overall general safety and tolerability  of albiglutide liquid drug product versus 
lyophilized drug product will be evaluated in tabular and/or graphical format and 
summariz ed descriptively.
The secondary  endpoint FPG change from baseline at Week [ADDRESS_484910] -years of overall exposure to date (including 
over [ADDRESS_484911] -years of exposure to albiglutide) and has been found to have a 
favorable benefit:risk profile, including a low immunogenicity  profile.  In the clinical 
program with the l yophilized product, a low incidence (4.4%) of ADA was detected. 
Antibodies were non -neutralizing and mostly  low titer and transient in nature.  None of 
the antibodies impacted the pharmacokinetic (PK), PD or efficacy  of the drug.  There was 
a higher frequency  of ISRs in antibody  positive subjects, however most subjects with an 
ISR (including those ISRs classified as serious) were antibod y negative.  There was no 
apparent relationship between antibody positive status and other AEs that could b e 
attributed to albiglutide. 
This repeat -dose study  in T2DM patients will determine if there are any  clinically  
relevant differences between liquid drug product stored under recommended storage 
conditions to ly ophilized drug product with respect to effica cy, safety , tolerability  and PD 
response. Specificall y, the immunogenicit y potential (e.g., incidences of ADA) and ISRs 
will be evaluated as part of the overall safet y assessment in this study .
2.2. Brief Background
Diabetes affects an estimated 347 million peo ple worldwide, T2DM accounting for more 
than 90% of cases [ World Health Organization, 2013]. The primary  manifestation of this 
disease is chronic h ypergly cemia, resulting from resistance to insulin action at a cellular 
and molecular level and a relative inadequacy  in the secretion of endogenous insulin 
[American Diabetes Association , 2014]. Chronic hy pergly cemia has been firmly  
established as a key  factor in the development of microvasc ular complications 
2014N210004_02 CONFIDENTIA L
200952
14(retinopath y, nephropathy, and neuropathy) and to a lesser extent, macrovascular 
complications. The rapi[INVESTIGATOR_387013] T2DM is a major 
worldwide healthcare issue due to increased patient morbidity  and mortalit y and the costs 
associated with the management of these complications.
The management of gl ycemia in individuals with T2DM consists of diet, exercise, and 
weight reduction together with oral anti -diabetic drugs, injectable agents such as GLP -1 
receptor agonists or insulin therapy , to achieve near normogl ycemia as reflected b y a 
target HbA 1clevel of  7%, where possible, without significant hy poglycemia or other 
adverse effects of treatment. Despi[INVESTIGATOR_387014], a 
high pr oportion of subjects fail to achieve or maintain target HbA 1clevels [ Khunti , 2013] 
owing to the inexorable decline in endogenous insulin production characteristic of the 
disease, and limitations in existing treatment s. New agents with complementary  
mechanisms (permitting combination use) or more favorable safet y profiles are needed to 
help more subjects achieve gl ycemic targets.
Glucagon -like peptide-1 receptor agonists (e.g., exenatide, liraglutide, lixisenatide, 
dulaglutide) are therapeutic agents for the treatment of T2DM that stimulate insulin 
secretion in a glucose -dependent manner, suppress glucagon secretion with a low risk of 
hypoglycemia, delay gastric empty ing, increase satiety , and are associated with modest
weight reduction. The GLP -1R agonists lower FPG levels and reduce postprandial 
glucose excursions. In addition, in preclinical models GL P-1R agonists stimulated 
transcription of genes important for glucose -dependent insulin secretion and promoted 
-cell neogenesis [ Gautier , 2005]. 
Albiglutide is a novel analogue of GLP -[ADDRESS_484912] to diet and 
exercise, as monotherap y, or in combination with existing therapi[INVESTIGATOR_014] (oral antidiabetic 
therapi[INVESTIGATOR_387015]). I t has been granted marketing authorization by  [CONTACT_23357] 
(March 2014), the FDA (April 2014), Switzerland (Sep 2014) and Health Canada (2015). 
Details of the clinical trial results can be found in the Investigator Brochure (IB).
2014N210004_02 CONFIDENTIA L
200952
153. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To evaluate the efficacy of albiglutide 
liquid prod uct as measured by [CONTACT_387047] (HbA 1c) change from baseline 
at Week 26.Change from baseline in HbA1c at 
Week26
Secondary
To assess safety and tolerability of 
albiglutide specifically immunogenicity 
and ISRs.Adverse events (AEs) and serious AEs 
(SAEs), physical examinations, clinical 
laboratory evaluations, vital signs, and 
12-lead electrocardiograms (ECGs).
Anti-albiglutide antibody production and 
rates of ISRs over time.
To evaluate the PD effect of albiglutide on 
fasting plasma glucose (FPG) change 
from baseline at Week 26.Change from baseline in FPG at Week 26
To assess the PD effect of albiglutide 
over timeChange from baseline in HbA1c over time
Change from baseline in FPG over time
To evaluate trough PK concentrations of 
albiglutide fol lowing repeat dosingTrough concentrations of albiglutide
4. STUDY DESIGN
4.1. Overall Design
This is a phase III, randomized, double -blind, multicenter, parallel -group, repeat -
dose, study  of [ADDRESS_484913]. 
The study  will recruit subjects with T2DM who are failing to achieve optimal 
glycemic control on their current regimen of diet and exercise or stable dose o f 
metformin . Subjects will continue on their current regimen for the duration of their 
participation in the study .
An overview of the stud y design is provided in Figure 1 : 
2014N210004_02 CONFIDENTIA L
200952
16Figure 1 Study  Schematic
Screening
Study  Week 0Albiglutide activ e lyophiliz ed DCC pen inj ector1+ 
placebo liquid autoinjector (N= 150)Albiglutide activ e liquid autoinj ector1+ placebo 
lyophiliz ed DCC pen inj ector    (N= 150)Treatment Period
−2
Primary  EndpointT2DM
HbA1c 7% to 10%
34 26Extension Study
or
Follow -up2
Baseline/
Randomization
DCC dual chamber glass cartridge
1. At baseline/randomization, albiglutide will be started at [ADDRESS_484914] (see Section 5.5), were withdrawn 
from the study, or who have completed the 26 week treatment period, but do not consent and/or are not eligible to 
participate in the 26 week extension study (Study 204682 ).
During the screening period, subjects will provide written informed consent and 
undergo procedures to determine eligibility  for study  participation .Screening will 
occur within 2 weeks of randomization. (Time and Events Table Section 7.1).
At randomization, subjects will be stratified by [CONTACT_654] (<65 or ≥65 y ears of age), weight 
(<90 kg or ≥90kg), and background antidiabetic therapy  (diet and exercise or stable 
dose of metformin).
Subjects who complete dthe [ADDRESS_484915], and meet all eligibility  criteria may  consent to participate in 
Study  204682, a 26 week extension study . 
4.2. Treatment A rms and Duration
This study  will comprise 3 study  periods ( Figure 1 ): screening (2 weeks), treatment 
(26 weeks) and for those subjects not entering the extension study  a follow -up period 
(8 weeks).
Subjects will be randomized in a 1:1 ratio to either: 
Albiglutide active liquid auto- injector  + placebo ly ophilized DCC pen injector; 
or,
Albiglutide active l yophilized DCC pen injector + placebo liquid auto -injector.
Study  treatment will be administered once weekl y by s.c. injection in the abdomen, 
thigh, or upper arm.
Study  personnel will administer study  treatment at cl inic visits.
2014N210004_02 CONFIDENTIA L
200952
17Subjects will receive 30 mg of albiglutide for 4 weeks and will then be up -titrated to 
50 mg albiglutide for the remaining 22 weeks of the study. 
Down -titration (dose reduction) of albiglutide from 50 mg to 30 mg is NOT 
permitted (see Section 4.4).  If a subject experiences tolerability  issues with the 
higher 50mg dose then the subject may discontinue investigational product (at the 
discretion of the investigator) and will be followed for safety  and efficacy .
During the study , any  potential events of pancreatitis will be adjudicated by [CONTACT_387050] (PAC) (Section 10.8).
4.3. Type and Number of Subjects
The study  will recrui t subjects with T2DM (>3 months since diagnosis) who are 
failing to achieve optimal gl ycemic control (HbA 1c7-10%) on their current regimen 
of diet and exercise or stable dose of metformin (maintained for approximately  8 
weeks prior to screening).
Approxim ately  [ADDRESS_484916]. 
The treatment dur ation of 26 weeks will also allow for appropriate evaluation of 
glycemic control as measured by  [CONTACT_13505] 1c and FPG.
The current study  is also apply ing the concept of design and objectives from the multiple -
dose phase of Stud y GLP114856 which demonstrated the clinical comparability  of 
Process 2 and Process 3 albiglutide l yophilized products in subjects with T2DM by 
[CONTACT_387051] 2 and 
Process 3 albiglutide ly ophilized products with regards to safet y and PD effects (i.e., 
HbA 1c, FPG) after [ADDRESS_484917] 2 years in man y subjects 
with T2DM, an increase in dose to 50 mg weekl y offered additional benefit without 
significant safet y issues (See IB for further details).
In this stud y subjects will receive [ADDRESS_484918] once weekl y for 4 weeks and will then be up -titrated 
to 50 mg albiglutide for the remaining 22 weeks of the study .
4.6. Benefit:Risk A ssessment
The following sections outline the risk assessment and mitigation strategy  for this 
protocol which w ould apply  to both the approved ly ophilized drug product and the new 
liquid drug product in development.
Albiglutide ly ophilized drug product has been evaluated in an international program of 
studies involving over [ADDRESS_484919] -years of exposure to albiglu tide. The program 
included 8 well -controlled Phase III studies ranging in duration from 32 weeks to 3 y ears, 
and using both 30 mg and 50 mg once weekly dosing.  This has permitted a thorough 
assessment of efficacy , safet y, and tolerability in a population of subjects with T2DM 
that spanned newl y diagnosed individuals treated with diet and exercise alone through to 
subjects on background oral monotherap y, oral dual therap y, oral triple therapy, and basal 
insulin.  
Summaries of findings from both clinical and non-clinical studies conducted with the 
albiglutide ([COMPANY_004]716155) ly ophilized drug product can be found in the IB and in the 
product labeling for those countries where marketing authorization has been granted. 
This is the first clinical investigation of t he albiglutide liquid drug product in subjects 
with T2DM. A detailed description of the characteristics of the liquid product in the auto -
injector device and results of nonclinical studies with this investigational drug product are 
presented in the IB Supp lement. 
Summary  characteristics of the liquid formulation and the ly ophilized formulation are 
shown in Table 1.
2014N210004_02 CONFIDENTIA L
200952
19Table 1 Composition of A lbiglutide (Liquid and Ly ophilized for Injection, 30 
mg/DCC and 50 mg/DCC)
ComponentLiquid Albiglutide Commercial Lyophilized Albiglutide
30 mg dose 50 mg dose 30 mg dose 50 mg dose
Injector typePre-filled syringe with auto -
injector  DCC in Pen injector 
Final formulation pH 5.9 7.0
Final albiglutide
concentration50 mg/mL 60 mg/mL 100 mg/mL
Injection volume 0.[ADDRESS_484920] -related variants/impurity  profiles are 
present in the liquid and commercial l yophilized products when stored at the 
recommended conditions.  Based on the current understanding of albiglutide degradation 
pathway s and clinical outcomes from exposure to variants/impurities; similar PK, PD, 
and clinical comparability between the liquid product and the l yophilized product is 
expected. 
4.6.1. Risk A ssessment
Key identified and potential risks associated with administration of albiglutide 
formulations in this study and mitigation strategies included in the protocol are 
summarized in Table 2. At this stage, the risk profile and associated pharmacovigilance 
and mitigation strategies are considered generally applicable to both the approved 
lyophilized product and the investigational liquid auto -injector. No risks specific to the 
liquid product have been identified in non -clinical studies to date.  Mitigation strategies 
for this study  have been incorporated for those risks (e.g. immunogenicity , ISRs) where a 
potential for differences between the formulations have been recognized.
Please also refer to the IB and an y IB supplements as well as the complete Guidance for 
the Investigator and local approved product labeling.
2014N210004_02 CONFIDENTIA L
200952
20Table 2 Risk A ssessment for Albiglutide ([COMPANY_004]716155 )
Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Identified Risks
Pancreatitis Acute pancreatitis has been reported in association with 
albiglutide and other GLP -1 receptor agonists in clinical 
trials and durin g postmarketing experience.
Albiglutide has not been studied in subjects with a history 
of pancreatitis to determine whether they are at increased 
risk for pancreatitis. Subjects with a history of acute or chronic pancreatitis are 
excluded from entering t he study (See Section 5.2).
Subjects will be informed of the characteristic symptom of 
pancreatitis: persistent severe abdominal pain. If 
pancreatitis is suspected, albiglutide should be promptly 
discontinued an d if pancreatitis is confirmed, study 
treatment will not be restarted (see Section 5.5).
Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for subjects.
Gastrointe stinal (GI) events. Albiglutide has not been studied in subjects with severe GI 
disease, including severe gastroparesis. 
Use of albiglutide can be associated with GI side effects 
such as diarrhea, nausea, and vomiting.Subjects with severe gastroparesis a re excluded from 
entering the study (See Section 5.2).
Subjects with a history of significant GI surgery that in the 
opi[INVESTIGATOR_387016] (See Section 5.2).
Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for subjects.
2014N210004_02 CONFIDENTIA L
200952
21Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
Hypoglycemia. Albiglutide’s mechanism of a ction is associated with a low 
intrinsic risk of significant hypoglycemia when used as 
monotherapy or in combination with agents such as 
metformin which also have low intrinsic risk for significant 
hypoglycemia . To reduce the risk of hypoglycemia when st arting 
albiglutide all subjects are required to have HbA1c ≥7.0 at 
screening (see Section 5.1). 
Subjects are neither allowed to use insulin nor insulin 
secretagogues during the study except as part of 
hyperglyc emia rescue (see Section 5.4)
Risk communication via guidance for investigators (see the 
albiglutide IB) and informed consent form for subjects.
Immunogenicity 
(e.g., including anti- drug antibodies, clinical s equelae of 
antidrug antibodies, severe hypersensitivity reactions, and 
other potential immune -related AEs).Risk assessment of the albiglutide molecule predicted low 
immunogenic potential, which was substantiated for the 
commercial lyophilized DCC pen inje ctor product in the 
registration program. Treatment -emergent anti -drug 
antibodies were detected in ~5 % subjects over studies of 
up to 3 years duration and were generally transient, of low 
titer, and not neutralizing.
Subjects who tested positive for anti -albiglutide antibodies 
experienced a similar glycemic response (HbA1c and 
fasting plasma glucose) to those who did not test positive 
for antibodies. Other than injection site reactions (see 
below), the overall safety profile appeared similar among 
the subse t of subjects who did and those who did not test 
positive for anti- albiglutide antibodies. 
Changes in the propensity of the liquid product to form 
aggregates could have an impact on anti -drug antibody 
characteristics or immune related AEs.  However, the 
likelihood of clinically important changes in anti -drug 
antibody characteristics or immune related AEs with the 
liquid albiglutide drug product compared to the lyophilized 
drug product is considered low based on the absence of 
substantive qualitative differ ences between formulations.A pre -exposure baseline serum sample will be taken and 
tested for pre -existing ADAs .
The development of anti -albiglutide antibodies will be 
assessed as part of this study.
Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for the subject.
Hypersensitivity Reactions Systemic allergic/hypersensitivity reactions are of potential 
concern with any injected protein and were reported rarely 
in the Phase III progr am with lyophilized albiglu tide. D ata Subjects with a known allergy to albiglutide or any product 
components (including yeas t and human albumin) are 
2014N210004_02 CONFIDENTIA L
200952
22Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
have not demonstrated an association of albiglutide with 
an increased incidence of anaphylaxis, angioedema, or 
urticaria. However, there was one non -serious 
hypersensitivity event (rash and itching associated with 
dyspnea upon rechallenge) that was consistent with a 
possible albiglutide -related systemic hypersensitivity 
reaction in a female subject who was anti -albiglutide 
antibody negative. See albiglutide IB.excluded from the study (See Section 5.2).  
Subjects will be informed of the symptoms of severe 
hypersensitivity or allergy and be advised to seek medical 
assistance immediately. 
Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for subjects.
Injection site reactions (ISRs) Albiglutide injections may cause rash, erythema or itching 
and/or other reactions at the site of injection. 
In the P hase III program with the lyophilized drug product, 
most subjects with ISRs did not test positive for anti -
albiglutide antibodies. However, injection site reactions 
were reported more frequently among those who did test 
positive for anti- albiglutide antibo dies (41% of the ADA 
positive subjects reported one or more injection site 
reactions) than among those who were consistently 
antibody negative (14% of the antidrug antibody negative 
subjects reported one or more injection site reactions).  
Overall, for al biglutide, injection site reactions have not 
been associated with clinically significant sequelae; 
although they can be a tolerability issue and were the most 
common reason for withdrawal of study medication for 
subjects (approximately 2.0 %) in the albiglu tide group.
Differences between formulation characteristics (e.g. lower 
pH and larger volume for the 50 mg dose of the liquid 
formulation) may impact the injection site reaction profile.Subjects will be advised that when injecting in the same 
region, to u se a different injection site each week.
Risk communication via guidance for investigators ( see 
albiglutide IB) ) and informed consent form for subjects.
The development of injection site reactions will be 
assessed as part of this study w here the investigat or or 
designee will administer both the albiglutide liquid drug 
product and the albiglutide lyophilized drug product .
Other adverse reactions
(e.g., pneumonia, atrial fibrillation/atrial flutter, and 
appendicitis) In the Phase III program in T2DM, other possible 
albiglutide related adverse reactions were identified. These 
events occurred at a cumulative incidence <3% in studies 
up to 3 years in duration. These events were reported 
more frequently with albiglutide than comparators . See 
albiglutide IB .Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for subjects.
2014N210004_02 CONFIDENTIA L
200952
23Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Potential Risks
Thyroid C -cell tumors GLP-1 receptor agonists, including albiglutide increas e 
serum calcitonin in rodents and other GLP -1 receptor 
agonists are associated with thyroid C- cell focal 
hyperplasia and C -cell tumors in rodents  It is unknown 
whether GLP -1 receptor agonists are associated with 
thyroid C -cell tumors in humans, including medullary 
thyroid cancer (MTC). Subjects with a personal or family history of MTC or 
subjects with Multiple Endocrine Neoplasia syndrome type 
2 (MEN -2) are excluded from the study (See Section 5.2).
Subjects w ith treatment emergent thyroid nodules should 
be referred to a specialist for evaluation in accordance with 
local treatment guidelines.  Routine monitoring of serum 
calcitonin is not recommended.  However, if serum 
calcitonin is found to be elevated the su bject should be 
referred to a specialist for further evaluation. If MTC or 
other thyroid C -cell neoplasia is diagnosed, study 
treatment will be discontinued (see Section 5.5).
Other malignant neoplasms Theoret ical concerns have been raised regarding use of 
incretin based therapi[INVESTIGATOR_387017] [ Egan , 2014] and malignancy when 
used in combination with insulin based on hypotheses of 
biological plausibility [ European Public Assessment 
Report , 2014], and hematological malignancies [ FDA
Summary Basis of Approval, 2014].Relevant data on pancreatic cancer are summarized in t he 
albiglutide IB .
Subjects with a history of cancer that has not been in full 
remission for at least 3 years before screening are 
excluded from the study (See Section 5.2).A history of 
squamous cell or basal c ell carcinoma of the skin or 
treated cervical intra -epi[INVESTIGATOR_28601] I or II is allowed.
Cardiovascular (CV) safety of antidiabetic therapy T2DM is associated with an elevated risk of CV disease. 
Global regulatory agencies require new antidiabetic 
therapi[INVESTIGATOR_387018]. 
In the Phase III registration program, an independent 
Clinical Endpoint Committee prospectively adjudicated 
blinded CV events. The final CV meta -analysis showed no 
increased CV risk (MACE [major adverse cardiovascular 
event] + composed of CV death, myocardial infarction [MI], 
stroke, and hospi[INVESTIGATOR_10929]) with 
albiglutide versus all comparators (MACE+ hazard ratio = Relevant data on cardiovascular events are summarized in 
the albiglutide IB .
Subjects with clinically significant CV and/or 
cerebrovascular disease within 3 months before scre ening 
will be excluded from the study. Further details are 
provided in Section 5.2
2014N210004_02 CONFIDENTIA L
200952
24Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
1.00; 95% CI: 0.68, 1.49). See Section 5.4of the IB.
Hepatotoxicity Hepatotoxicity is an area of interest in drug development.  
Patients with T2DM are at increased risk for liver enzyme 
abnormalities and disease related liver conditions.  One 
subject treated with albiglutide in the Phase III clinical 
program developed probable drug induced liver injury with 
an asymptomatic elevation in alanine amino transferase 
(ALT) and total bilir ubin although the cases had some 
atypi[INVESTIGATOR_387019] . Routine liver safety laboratory evaluations will be 
conducted and specific withdrawal criteria for elevated liver 
function tests have been defined (See Section 5.5.4 ).
2014N210004_02 CONFIDENTIA L
200952
25Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Additional Considerations
Subject population with severe renal impairment 
(estimated glomerular filtration rate (eGFR) 
<30mL/min/1.73m2)Experience in T2DM subjec ts with severe renal impairment 
is limited (in the Phase III programme a total of 19 subjects 
with eGFR <30 mL/min/1.73m2received albiglutide). 
In a Phase III study of patients with varying degrees of 
renal impairment, in the albiglutide group, on -therapy GI 
AEs occurred with a higher incidence and higher event rate 
in subjects with moderate and severe renal impairment 
compared to those with mild renal impairment. GI events 
may lead to dehydration and worsen renal function. Subjects with an eGFR ≤30 mL/m in/1.73 m2(calculated 
using the Modification of Diet in Renal Disease (MDRD) 
formula) are excluded from the study (see Section 5.2).
Risk communication via guidance for investigators (see the 
albiglutide IB ) and informed consent form for subjects.  
Drug interactions Albiglutide causes a delay in gastric emptying, and thereby 
[CONTACT_387052].
During the development program, drug interactions 
studies were conducted with digoxin, warfarin, oral 
contraceptives, and simvastatin which demonstrated no 
clinically relevant PK or PD effects. Investigators will be advised to take the effect of albiglutide 
on gastric emptying into account when pre scribing 
concomitant medication.
Fetal & neonatal developmental toxicity Studies in animals have shown reproductive toxicity. The 
potential risk for humans is unknown.  Albiglutide 
administration during the major period of organogenesis in 
female mice resulted in embryofetal lethality, and 
bent/wavy ribs in the fetus at 50 mg/kg/day.  Offspring of 
mice dosed with 50 mg/kg/day during organogenesis had 
reduced pre -weaning body weight (which recovered after 
weaning), dehydration and coldness, and a delay in 
balanopreputial separation.
Given that albiglutide is an albumin -based protein 
therapeutic, it is likely to be transferred to breast milk. 
Decreased body weight in offspring was observed in mice 
treated with albiglutide during gestation and lactation.Subje cts who are breastfeeding, pregnant or planning a 
pregnancy during the course of the study are excluded. 
Additionally, all females of child -bearing potential must be 
taking adequate contraception during the study and have a 
negative pregnancy test prior to entry.  See Section 5.1for 
further details.
Risk communication via guidance for investigators (see IB) 
and informed consent form for subjects.
2014N210004_02 CONFIDENTIA L
200952
26Potential Risk of Clinical Significance Summary of Data/R ationale for Risk Mitigation Strategy
Accelerated sexual maturation in juveniles Long -acting GLP -1R ago nists have the potential to 
accelerate sexual maturation in monkeys based on 
absolute testes weight and similar trends in prostate, 
seminal vesicle, epi[INVESTIGATOR_387020].Subjects under 18 years of age are excluded ( see Section 
5.1).
Study Procedures
Albiglutide matching placebo injections Albiglutide placebo injections using the lyophilized DCC 
pen injector were associated with a clinically relevant rate 
of injection sit e reactions in the Phase III studies.
There is no experience with placebo injections using the 
liquid auto -injector, including volume and pH differences 
from the lyophilized product placebo.Subjects will be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via informed consent form for 
subjects.
2014N210004_02 CONFIDENTIA L
[ADDRESS_484921] resulted in 
clinically  relevant lowering of HbA 1cat both the 30 mg and 50 mg doses when given as 
monotherap y and in combination with metformin, sulfonylureas (SUs), thiazolidinedione 
or basal insulin. The durability  of the effect on gl ycemic control was shown over a stud y 
period of up to [ADDRESS_484922] s and clinical 
outcomes from exposure to variants/impurities clinical comparabil ity between the liquid 
drug product and l yophilized drug products is expected.
4.6.3. Overall Benefit: Risk Conclusion
Taking into accou nt the measures taken to minimiz e risk to subjects participating in this 
study , the known and potential risks identified with a lbiglutide are justified by  [CONTACT_387053] T2DM.
2014N210004_02 CONFIDENTIA L
[ADDRESS_484923] will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
[1] AGE
1.Aged 18 to 80 y ears of age inclusive, at the time of signing the informed consent.
[2] TYPE OF SUBJECT AND DIAGNOSIS I NCLUDING DI SEASE SEVERI TY 
2. Historical diagnosis of T2DM (at least 3 months), experiencing inadequate gl ycemic 
control on current regimen of diet and exercise or on a stable dose of metformin of at 
least 1500 mg or the documented maximal tolerated dose if less than 1500 mg 
metformin (monotherap y), maintained for approximately  8 weeks prior to screening
3.HbA 1c≥7.0% and ≤10%. If the first screening HbA 1cdoes not meet the eligibility  
criterion, the HbA 1cvalue may  be checked up to [ADDRESS_484924] can be randomly  
assigned to treatment.
4.Hemoglobin ≥11 g/dL (≥110 g/L) for males and ≥10 g/dL (≥100 g/L) for females.
[3] WEIGHT
5.Body mass index 40kg/m2.
[4] SEX
6.Male or femal e
7.Female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative serum human chorionic gonadotrophin (hCG) test for females of 
reproductive potential only ), not breastfeeding, and at least one of the following 
2014N210004_02 CONFIDENTIA L
200952
29conditions appli es:
a)Reproductive potential and agrees to follow one of the options listed in the [COMPANY_004] 
Modified L ist of Highl y Effective Methods for Avoiding Pregnancy  in Females 
of Reproductive Potential (FRP) (eg., combined oral contraceptive pi[INVESTIGATOR_4382]; see 
Appendix 2 ) from [ADDRESS_484925] dose of study  medication and completion of the follow -up visit.
This does not apply  to FRP with same sex partners, when this is their preferred
and usual lifesty le or for subjects who are and will continue to be abstinent. 
Other situations in which contraception in FRP may not need to be mandated 
should be discussed with the Medical Monitor.
b)Non-reproductive potential defined as either:
Pre-menopausal with one of the following: (i) documented tubal ligation; (ii) 
documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion; (iii) hy sterectom y; or (iv) documented 
bilateral oophorectomy , or; 
Postmenopa usal defined as 12 months of spontaneous amenorrhea and age 
appropriate (i.e., >50 years). In questionable cases, a blood sample with 
simultaneous follicle stimulating hormone (FSH) >40 mIU/mL  and estradiol 
<40pg/mL (<140 pmol/L) is confirmatory ,dependin g on local laboratory  
ranges .  Females on hormone replacement therapy  (HRT) and whose 
menopausal status is in doubt will be required to use one of the highl y effective 
contraception methods if they  wish to continue their HRT during the stud y.  
Otherwise, t hey must discontinue HRT to allow confirmation of post -
menopausal status prior to study  enrolment.
[5] INFORMED CONSENT
8.Able and willing to provide informed consent.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
[1]  CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1.Type [ADDRESS_484926] 3 y ears before 
screening. (A history  of squa mous cell or basal cell carcinoma of the skin or treated 
cervical intra -epi[INVESTIGATOR_28601] I or II is allowed).
3.Personal or famil y history of medullary  thyroid carcinoma or multiple endocrine 
neoplasia ty pe 2. 
4.History  of acute or chronic pancreatitis.
5. Abnormal (i.e., outside the normal reference range) thy roid stimulating hormone 
2014N210004_02 CONFIDENTIA L
200952
30(TSH) at screening.
6. Severe gastroparesis, i.e., requiring regular therapy within [ADDRESS_484927] upper GI or pancreatic function (e.g., gastric b ypass and banding, 
antrectom y, Roux -en-Y by [CONTACT_6476], gastric vagotom y, small bowel resection, or 
surgeries thought to significantly  affect upper GI function).
8.History  of se vere h ypoglycemia unawareness (i.e., the absence of autonomic warning 
symptoms before the development of neurogl ycopenic symptoms such as blurred 
vision, difficulty  speaking, feeling faint, difficulty thinking, and confusion)..
9.Diabetic complications (e.g. , active proliferative retinopathy  or severe diabetic 
neuropath y) or an y other clinically significant abnormality (including a ps ychiatric 
disorder) that, in the opi[INVESTIGATOR_871], may  pose additional risk in 
administering the investigational pro duct.
10.Clinically  significant CV and/or cerebrovascular disease within 3 months before 
screening including, but not limited to, the following: 
Stroke or transient ischemic attack.
Acute coronary  syndrome (MI or unstable angina not responsive to 
nitrogl ycerin).
Cardiac surgery  or percutaneous coronary  procedure.
Current or history  of heart failure ([LOCATION_001] Heart Association class III or IV).
11. QTcF > 470 msec, where QTcF is the QT interval corrected for heart rate according 
to Fridericia’s formula.
12.ALT >2.5xU LN or bilirubin >1.5xUL N (isolated bilirubin >1.5xUL N is acceptable 
if bilirubin is fractionat ed and direct bilirubin <35%). 
13. Current active liver or biliary  disease (with the exception of Gilbert’s s yndrome or 
asymptomatic gallstones or otherwise stable c hronic liver disease per investigator 
assessment). 
NOTES: 
Stable chronic liver disease should generally  be defined by  [CONTACT_387054], encephalopath y, coagulopath y, hypoalbuminaemia, oesophageal or 
gastric varices, or persistent jaundice, or cirrh osis.
Chronic stable hepatitis B and C (e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody test result at screening or within [ADDRESS_484928] dose of study  treatment) are acceptable if subject otherwise 
meets ent ry criteria.
14.eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula) at screening.
Note: The use of metformin in subjects with varying degrees of renal function   
should be in accordance with the metformin product label.
2014N210004_02 CONFIDENTIA L
[PHONE_8066].Hemoglobinopath y that may affect proper inte rpretation of HbA 1c.
16.Medical or ps ychiatric disorders that would preclude effective participation in study .
[2] CONCOMITANT MEDI CATIONS (see Section 6.10 )
17.Use of oral or s ystemically  injected glucocorticoids within the 3 months before 
randomization or high likelihood of a requirement for prolonged treatment (>1 week) 
in the 6 months following randomization. However, short courses of oral steroids 
(single dose or multiple doses for up to 7 day s) may  be permitte d provided these 
cases are discussed with the medical monitor. Inhaled, intra-articular, epi[INVESTIGATOR_13873], and 
topi[INVESTIGATOR_88900].
18.Use of GLP 1 receptor agonists at an y time. Use of dipep tidyl peptidase -IV 
inhibitors within the 3 months before ran domization. Use of an y other antidiabetic 
medications with the exception of metformin within 3 weeks before randomization.
[3] RELEVANT HABITS
19.History  of alcohol or substance abuse within one y ear before screening.
[4] CONTRAI NDICATIONS 
20. Known allerg y to albiglutide or an y product components (including yeast and human 
albumin), any  other GLP -1 analogue, or other study  medication’s excipi[INVESTIGATOR_387021] (per the prescribing information) for the use of potential 
study  medications.
[5] DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
21.Positive urine alcohol/drug screen result at Screening, unless the subject is taking a 
medically  approved medication for which a positive drug screen simply  verifies the 
use of this medication 
22. A positive test for human immunodeficiency  virus (HIV) antibody .
23. The subject has participated in a clinical trial and has received an investigational 
product within the following time period prior to the first dosing day  in the current 
study : [ADDRESS_484929] (whichever is longer).
24.Fasting trigl yceride level >750 mg/dL at screening.
2014N210004_02 CONFIDENTIA L
200952
325.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjects who consent to participate in the cl inical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from regulatory  authorit ies, a minimal 
set of screen failure information is required including demograph y, screen failure details, 
eligibility  criteria, and any  SAEs.
Re-screening of subjects who did not meet the eligibility  criteria for HbA 1c(≥7.0% 
and ≤10%) is permitted. If the first screening HbA 1cdoes not meet the eligibility  
criterion, the HbA 1cvalue may  be checked two further times during the screening 
period, and if the average of these determinations meets the entry  criterion, the 
subject can be randomized.
5.4. Hypergly cemia Rescue
During the study  of diabetics, there is alway s the possibility  of hypergl ycem ia, which 
might impact subject safety . After randomization, subjects who experience persistent 
hypergly cemia will qualify  to undergo h yperglycemia rescue. Investigators must adhere 
to the labeling of the US FDA -approved prescribing information or to the local labeling 
of the respective country  for all rescue medications. The conditions for hy pergly cemia 
rescue are defined in Table 3.
Table 3 Conditions for Hyperglycemia Rescue
Time Interval on Treatment Hyperglycemia Rescue
≥Day 1 and <Week 2 No rescue
≥Week 2 and <Week 4 FPG ≥280 mg/dL1 
≥Week 4 and <Week 12 FPG ≥250 mg /dL1
≥Week 12 and <Week 26 HbA1c ≥8.5% and 0.5% reduction from Baseline
1. Confirmed by a second sample drawn within [ADDRESS_484930] complete and unbiased follow- up of long -term safet y and efficacy  
assessments. 
The rescue criteria above should apply  in the majority  of circumstances; however, in the 
event a subject experiences significant evidence of hy perglycemia (e.g., s ymptoms of 
polyuria and poly dipsia and laboratory  evidence of hy pergl ycemia), the investigator may , 
based upon his or her judgment, rescue the subject with appropriate therap y at an y time 
following randomization. Such subjects may  either h ave rescue medication added to the 
2014N210004_02 CONFIDENTIA L
200952
33existing randomly  assigned study  medication or, if in the judgment of the investigator (or 
the product labeling for rescue medications) this is not appropriate, the subject will be 
discontinued from randomly  assigned stud y medication and appropriate rescue therap y 
initiated. Such subjects will continue to be followed in the study  for their safety  
information; however, they  will not receive further randoml y assigned study medication. 
Rather they  will be prescribed alternati ve therap y in order to optimize their diabetes 
control.
The preferred postrescue add -on treatment is insulin. Other medications may  be added at 
the investigator’s discretion. The addition of other GL P-1 analogues (exenatide or 
liraglutide) is prohibited as the safet y of dosing with multiple GL P-1 analogues is 
unknown. The use of dipeptidy l peptidase- IV inhibitors is prohibited. The addition of a 
thiazolidinedione (rosiglitazone or pi[INVESTIGATOR_051]) is discouraged.
5.5. Withdrawal/Stoppi[INVESTIGATOR_387022] d be made to keep subjects in the study. The reason for a subject 
discontinuing investigational product or withdrawing from the stud y will be recorded in 
the subject’s electronic case report form (eCRF). 
5.5.1. Permanent Discontinuation of Investigational Produc t
A subject may  permanently  discontinue investigational product at an y time at his/her own 
request, or at the discretion of the investigator for safet y or compliance reasons.  A 
subject must permanently  discontinue investigational product for the pre -speci fied 
reasons below. 
Any AE, which, in the opi[INVESTIGATOR_387023] a safety  concern
The following AEs will require discontinuation from investigational product:
Confirmed pancreatitis, acute or chronic. 
Pancreatic cancer.
Confirmed MTC or other thy roid C -cell neoplasia.  
Liver chemistry  abnormalities exceeding the threshold criteria outlined in 
Section 5.5.4
QTc abnormalities exceeding the threshold criteria outlined in Section 5.5.5.
Severe allergic/h ypersensitivity  reactions that are considered b y the 
investigator to be attributable to investigational product or without a likely 
alternative aetiology .
eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula).
Subject becomes pregnant or intends to become pregnant during the stud y.
Need for chronic use of a prohibited concomitant medication (Section 6.10.2 )
2014N210004_02 CONFIDENTIA L
200952
34Major protocol deviation (the investigator should discuss the protocol deviation with 
the medical monitor before withdrawing stud y medication)
Subject decision (reason to be documented in the eCRF, if specified b y the subject)
Investigator discretion 
Study  closed/terminated or investigator site closed (where subject transfer to another 
site is not possible)
In all cases, the reasons for investigational product discontinuation and the date of the last 
dose will be recorded in the subject’s electronic case repo rt form (eCRF) and the subject 
will continue in the study as described in 5.5.1
[IP_ADDRESS]. Procedures for Subject Follow -up Follo wing Discontinuation of 
Investigational Product
Subjects will be educated on the importance o f remaining in the study  and attending all
scheduled stud y visits. 
Subjects who permanently discontinue investigational product will be expected to attend 
clinic visits every  4 weeks through the End of Treatment visit, according to the study  visit 
schedul e, unless consent is actively  withdrawn. Complete details are provided in the 
Time and Events Table (Section 7.1
).
If a subject is unable or unwilling to continue attending clinic visits in person, other 
subject follow -up options to collect subject information as detailed in the informed 
consent (e.g., telephone calls, letters, review of subjects medical records) should be 
pursued.
5.5.2. Subjects Who Fail to Attend Clinic Visits
The following actions must be taken in r elation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as soon 
as possible. 
The site must counsel the subject on the importance of maintaining the assig ned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in 
the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or designee 
must make every  effort to regain contact [CONTACT_1155] (wh ere possible, [ADDRESS_484931]’s last known mailing address or 
local equivalent methods). These contact [CONTACT_244181]’s medical record. 
Should the subject continue to be un reachable, only  then will he/she be considered to 
have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484932]’s eCRF. If a subject withdraws from the stud y, he/she may request 
destruction of an y samples taken, and the investigator must document this in the site 
study  records. 
Subjects who are withdrawn or discontinue active participation in the study  will no 
longer receive the randomized study  treatment. Immediately  upon discontinuation from 
active participation in this study , these subjects should complete the assessmen ts as per 
the end of treatment clinic visit and return for the post- treatment follow -up clinic visit 8 
weeks later (Section 7.1). If a subject is unable or unwilling to return for the follow-up 
assessments, ever y effort will be made to follow -up with the subject.
Withdrawn subjects will not be replaced. 
5.5.4. Liver Chemistry Stoppi[INVESTIGATOR_387024] -IV Liver Chemistry Stoppi[INVESTIGATOR_387025]≥2x
ULN (>35% 
direct) or plus
INR>1.5, if 
measur ed*
Possi ble  
Hy’sLawALT≥3xULNALT
≥8xULNPlus
Sympt oms of 
liver injury
or 
hyper sensitivityNo
Yes
Yes YesNo No NoSee algor ithm 
for continued  
therapy with 
increase d liver 
chemi stry 
monitoring
Yes
*INR value not applicable to subjects on anticoagu lants ALT 
≥3xULN 
but 
<8xULNYes
Must  refer to Liver S afety  Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
2014N210004_02 CONFIDENTIA L
200952
36Liver Safet y Required Actions and Follow up Assessme nts Section can be found in 
Appendix 3 .
Phase III -IV Liver Chemistry Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <8xULN
Cont inue Study Treatment   and   Monitor Liver Chemistry
Discontinue Study T reatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other 
stoppi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other 
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xU LN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 3 .
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_387026].
5.5.5. QTc Stop pi[INVESTIGATOR_2121]
The QT interval corrected for heart rate according to Fridericia’s formula (QTcF) 
must be used for each individual subject to determine eligibility  for and 
discontinuation from the study .  
The QTcF should be based on a single electrocardiogr am (ECGs) obtained over a 
brief (e.g., 5 -10 minute) recording period.  
A subject who meets the following criteria will discontinue investigational product :
QTcF >500 msec (or  530 msec for subjects with bundle -branch block or 
pacemaker)
2014N210004_02 CONFIDENTIA L
[ADDRESS_484933]’s last visit.
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘study treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design. Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
2014N210004_02 CONFIDENTIA L
[ADDRESS_484934] name: [CONTACT_387072] -injector Albiglutide liquid auto -injector 
matching placebo
Dosage 
form/Delivery 
system:Lyophilized albigluti de is 
provided as a fixed -dose, fully 
disposable pen injector 
system for delivery of the 
study treatment from a 
prefilled dual chamber glass 
cartridge (DCC) that is an 
integral part of the injector 
pen. It is designed for manual 
reconstitution of the dose,
priming and insertion of the 
pen needle (29G), and 
manual injection.
The DCC contains lyophilized 
albiglutide (30mg or 50mg). 
When the injector pen product 
is reconstituted a neutral, 
isotonic solution is produced. 
The pen delivers albiglutide in 
an injec tion volume of 0.5 mL.Lyophilized albiglutide 
matching placebo is provided 
as a fixed -dose, fully 
disposable pen injector 
system for delivery of the 
study treatment from a 
prefilled DCC that is an 
integral part of the injector 
pen. It is designed for manu al 
reconstitution of the dose, 
priming and insertion of the 
pen needle (29G), and 
manual injection.
The DCC contains matching 
placebo. When the injector 
pen product is reconstituted a 
neutral, isotonic placebo 
solution is produced. The pen 
delivers the pla cebo in an 
injection volume of 0.5 mL.Albiglutide liquid is provided 
as a fixed -dose, disposable 
auto-injector containing 
albiglutide liquid (30 mg or 
50mg) in a prefilled glass 
syringe with staked 29G thin -
wall needle and needle shield.  
It is intended for single use. 
The cap remover is removed 
and the cover sleeve of the 
auto-injector is pressed 
against the skin, which results 
in automatic s.c. injection of 
the albiglutide liquid.
Albiglutide liquid (30mg or 
50mg) has a pH of 5.9.
The auto -injector deli vers the 
study treatment in an injection 
volume of 0.[ADDRESS_484935] the skin, which results 
in automatic s.c. injection of 
the placebo liquid.
The placebo liquid has a pH 
of 5.9.
The auto -injector delivers the 
placebo in an injection volume 
of 0.6 mL for the 30 mg 
placebo dose and 1.0 mL for 
the 50 mg placebo dose.
2014N210004_02 CONFIDENTIA L
200952
39Study Treatment
Unit dose 
strength(s)
/Dosage level(s):30mg or 50mg albiglutide Matchi ng placebo 30mg or 50mg albiglutide Matching placebo
Route of 
AdministrationSubcutaneous injection in the 
abdomen, thigh or upper arm 
region.
Rotation of injection sites is 
recommended. Subcutaneous injection in the 
abdomen, thigh or upper arm 
region.
Rotation of injection sites is 
recommended. Subcutaneous injection in the 
abdomen, thigh or upper arm 
region.
Rotation of injection sites is 
recommended. Subcutaneous injection in the 
abdomen, thigh or upper arm 
region.
Rotation of injection sites is 
recommended. 
Dosing 
instructions:Administered as a single s.c. 
injection once a week on the 
same day each week.
Administered by [CONTACT_387055].
Administered at any time of 
day without regard to meals.Administered as a single s.c. 
injection once a week on the 
same day each week.
Administered by [CONTACT_387055].
Administered at any time of 
day without regard to mealsAdministered as a single s.c. 
injection once a week on the 
same day each week.
Administered by [CONTACT_387055].
Administered at any time of 
day without regard to mealsAdministered as a single s.c. 
injection once a week on the 
same day each week.
Administered by [CONTACT_387055].
Administ ered at any time of 
day without regard to meals
2014N210004_02 CONFIDENTIA L
200952
406.2. Treatment A ssignment
Randomized treatment assignment will be done via the Interactive Voice Response 
System (IVRS), and randomization will be implemented based on a sequestered fixed 
randomization schedule . Study  centre personnel will call the I VRS to execute each 
randomization once a subject has met all prerequisites for randomization and has 
completed all scheduled screening assessments.
Subjects will be assigned to study  treatment in accordance with the randomization 
schedule. Eligible subjects will be stratified by  [CONTACT_654] (<65 or ≥65 y ears of age), weight 
(<90 kg or ≥90kg), and background antidiabetic therapy  (diet and exercise or stable dose 
of metformin).
Subjects will be randomized in a 1:1 ratio to either: 
Albiglutide active liquid auto- injector  + placebo ly ophilized DCC pen injector; 
or,
Albiglutide active l yophilized DCC pen injector + placebo liquid auto -injector.
Blinded study  centre personnel will receive a randomization notification indicating onl y 
the unique subject identifie r and the date and time of randomization. Each subject number 
will be a unique identifier. Once a subject number has been assigned, the number will not 
be reused even if the subject withdraws before receiving an y stud y treatment. 
6.3. Planned Dose A djustments
Subjects will receive [ADDRESS_484936] during Weeks 1- 4 and will then be up
-titrated to 50 mg 
albiglutide for the remaining 22 weeks of the study (Weeks 5 -26).  
Down -titration (dose re duction) of albiglutide from [ADDRESS_484937] (at the discretion of the investigator) and will be 
followed for safet y and efficacy .
The use of metformin in subjects with vary ing degrees of renal function should be in 
accordance with the metformin product label. It is encouraged that a stable metformin 
dose is maintained during the study. However the metformin dose may be downtitrated 
based on clinical need at the discretion of the investigator . Up-titration of metformin is 
permitted for subjects who require h yperglycemic rescue and metformin is selected as the 
rescue medication.
6.4. Blinding
This is a double -blind study ; neither the subject nor the study  physician will know which 
of the treatments ( albiglutide liquid auto -injector or matching placebo and lyophilized
albiglutide DCC pen injector or matching placebo) the subject is receiving. The following 
will apply . 
2014N210004_02 CONFIDENTIA L
200952
41Theinvestigator or treating ph ysician may  unblind a subject’s treatment assignment 
only in the case of an emergency OR in the event of a serious medical condition 
when knowledge of the study  treatment is essential for the appropriate clinical 
management or w elfare of the subject as judged b y the investigator. 
Investigators have direct access to the subject’s individual study  treatment. 
It is preferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  person nel to discuss options before unblinding 
the subject’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the treatment 
assignment of the unblinded subject, unless that information is important for the 
safet y of subjects currently in the study. 
The date and reason for the unblinding must be fully  documented in the eCRF 
If the subject’s treatment code is unblinded by  [CONTACT_387056] 5.5. 
[COMPANY_004]’s Global Clinica l Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  subject with an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the subject’s treatment assignment, may  be sent to investigators in 
accordance with local regulations and/or [COMPANY_004] policy.
6.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.6. Preparation/Handling/Storage/A ccountability
No special preparation of study  treatment is required other than that described in Section 
6.1.
Only  subjects enrolled in the study  may  receive study  treatment and onl y authorized site 
staff may  suppl y and administer study  treatment.  All study  treatments must be stored in a 
secure environmentall y controlled and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorize d site staff. 
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y treatment accountability, reconciliation, and record maintenance 
(i.e. receipt, reconciliation and final disposition records). 
Further guidance and information for final disposition of unused study  treatment are 
provided in the Study  Reference Manual (SRM). 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484938] and the generation of aerosols or mists. I n the case of unintentional 
occupational exposure notify  the monitor, Medical Monitor and/or [COMPANY_004] study contact.
A Material Safety  Data Sh eet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from [COMPANY_004].
6.7. Compliance with Study  Treatment A dministration
The investigator or designee will administer study treatment to the subject in the clinic at 
the time points specified in the Time and Events Table (Section 7.1). The date and time 
of each dose admi nistered in the clinic will be recorded in the source documents. The 
dose of study  treatment and study  subject identification will be confirmed at the time of 
dosing b y a member of the study site staff other than the person administering the stud y 
treatment.
6.8. Treatment of Study  Treatment Overdose
No data are available with regard to albiglutide overdose in humans. The highest 
recommended dose of albiglutide is [ADDRESS_484939]’s clinical status. Anticipated sy mptoms of an overdose may  be severe nausea, 
vomiting or headache.  A prolonged period of observation and treatment for these 
symptoms m ay be necessary , taking into account the half- life of albiglutide (5 day s).
6.9. Treatment after the End of the Study
Following completion of the Week [ADDRESS_484940] consent to 
participate in the extension study  (Study  204682) will be trea ted as detailed in the 
extension study  protocol. Those subjects who did not give consent to participate in the [ADDRESS_484941] -treatment 
follow -up visit (Week 34 visit). 
Investigational produ ct will not be provided to subjects by  [CONTACT_387057] .
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, whether or not [COMPANY_004] is providing specific 
post-study treatment.
2014N210004_02 CONFIDENTIA L
[ADDRESS_484942] adhere to the local labeling of the respective country  (e.g., the 
Summary  of Product Characteristics (SmPC) in relevant European countries or the FDA -
approved prescribing information) for all permitted medications.
6.10.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_387027]:
Dipeptidy l peptidase- IV inhibitors and GL P-1R ago nists (except albiglutide liquid  
or lyophilized drug products taken as study  treatment) are prohibited.
Antidiabetic medications other than metformin and study  treatment (per study  
design) unless subjects require antidiabetic medication for hy pergl ycemic rescue.
The preferred post -rescue add -on treatment is insulin. Other medications may  be 
added at the investigator’s discretion. The addition of other GLP- 1 analogues (i.e., 
exenatide,  or liraglutide, lixisenatide, dulaglutide) is prohibited as the safety of 
dosing with multiple GLP 1 analogues is unknown. The use of dipeptid yl 
peptidase -IV inhibitors is prohibited. The addition of a thiazolidinedione 
(rosiglitazone or pi[INVESTIGATOR_051]) is discouraged.
Any investigational drug other than the study  treatment the y have been randomly  
assigned to.
2014N210004_02 CONFIDENTIA L
200952
44Oral or s ystemicall y injected corticosteroids (inhaled, intra -articular, epi[INVESTIGATOR_13873], and 
topi[INVESTIGATOR_88900]); short courses of oral steroids (single dose or 
multiple doses for up to 7 day s) may  be permitted provided these cases are 
discussed with the medical monitor
If a subject receives a prohibited medication, a protocol deviation will be reported and 
continuation in the study  will be discussed with and agreed upon by  [CONTACT_7195].
2014N210004_02 CONFIDENTIA L
[ADDRESS_484943] safety .
Study  visits between Baseline (Week 0) and End of treatment (Week 26) will have a visit 
window of ±3 day s and the follow -up visit (Week 34) will have a visit window of ±7 
days. If extraordinary  events that make it impossible for subjects to complete a 
visit/dosing within the visit wind ow (e.g., holidays, personal emergencies), the 
investigator should contact [CONTACT_387058].  
If a subject misses a weekly  scheduled visit for receiving albiglutide treatments, the 
albiglutide treatments should be administered as soon as pos sible within [ADDRESS_484944]’s next regularly  scheduled visit.  If a subject misses [ADDRESS_484945] the medical monitor to discuss options for helpi[INVESTIGATOR_387028].  The medical monitor shall make a decision (on a case b y case 
basis) on whether the subject should continue to receive investigation product.
2014N210004_02 CONFIDENTIA L
200952
467.1. Time and Events
Table 4 Schedule of A ssessments
ProcedureTreatment
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Week -2 0 1 2 3 4 5 6 7 8 9 10 11 12
Visit Window -14d 0d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d
Informed consent X
Demography/medical history X
HIV, hepatitis B and C, amylase, lipase, 
alcohol and drug  screen, TSHX
Inclusion/exclusion criteria review X X1
Full (F) or brief (B) physical exam2 F B B B
Height (H),Weigh (W), BMI H, W, 
BMIW W
12-lead ECG3 X X X X X
Vital signs3 X X X X X X X X X X X X X X
Serum (S)/Urine (U) pregnancy test 
(WCBP)S U U U U
Clinical chemistry/hematology samples4 X X X X
Lipi[INVESTIGATOR_805] (including total cholesterol, LDL -C, 
HDL C, triglycerides, FFAs)4X
Urinalysis5 X
HbA 1c 6,9 X X X X X X
eGFR X X X
Immunogenicity sample7 X X X X X
Genetic sample8 X
FPG 9 X X X X X X X X X X X X X
PK samples10 X
Review AE/SAE, concomitant medication 
and hypoglycemia events X X X X X X X X X X X X X X
Advice on diet and exercise11 X X X X X X X X X X X X X
Register visit into IVRS X X X X X X X X X X X X X X
Randomization12 X
Study Treatment X X X X X X X X X X X X X
2014N210004_02 CONFIDENTIA L
200952
47Table 4 Schedule of A ssessments
ProcedureTreatment End of 
Treatment
12,13Follow -
up14
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Week15 13 14 15 16 17 18 19 20 21 22 23 24 25 26 34
Visit Window ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±7d
Informed consent
Demography/medical history
HIV, hepatitis B and C, amylase, lipase, 
alcohol and drug  screen, TSH
Inclusion/exclusion criteria review
Full (F) or brief (B) physical exam2 B B B B F F
Height (H),Weigh (W), BMI W W W W W W
12-lead ECG3 X
Vital signs X X X X X X X X
Serum (S)/Urine (U) pregnancy test (WCBP) U U U U S U
Clinical chemistry/hematology samples4 X X
Lipi[INVESTIGATOR_805] (including total cholesterol, LDL -C, HDL 
C, triglycerides, FFAs)4X X
Urinalysis X
HbA 1c 5,8 X X X X
eGFR X X X
Immunogenicity sample6 X X X X X
Genetic sample7
FPG 8 X X X X X
PK samples9 X
Review AE/SAE, concomitant medication and 
hypoglycemia events X X X X X X X X X X X X X X X
Advice on diet and exercise10 X X X X X X X X X X X X X X
Register visit into IVRS X X X X X X X X X X X X X X X
Randomization11
Study Treatment X X X X X X X X X X X X X
TSH: thyroid stimulating hormone; BMI: body mass index; WCBP: women of child bearing potential; FFA: free fatty acids; LDL -c:  low density lipoproteins cholesterol; 
HDL-c: high density lipoproteins cholesterol ; d, day
2014N210004_02 CONFIDENTIA L
[ADDRESS_484946]’s eligibility. If a subject no longer meets all of the eligibility criteria (e.g., there is 
evidence of a new myocardial infarction (MI) on an ECG or ALT, etc. are out of range), do not administer the study treatment and conta ct the medical monitor to discuss how to 
proceed (e.g., to determine if repeat testing is warranted). 
2. Details of full and brief physical examinations are provided in Section 7.4.[ADDRESS_484947] their FPG and HbA 1clevels evaluated to monitor for potential hyperglycemia.
9. PK samples (troug h) will be obtained prior to dosing (Section 7.6).
10. Standard diabetic dietary and exercise advice will be provided at Visit [ADDRESS_484948]’s 
treatment assignment.
12. Subjects who discontinue study treatment should be handled as described in Section 5.5.
13. The end of treatment visit in Study 200952.is also Visit [ADDRESS_484949] (see Sectio n 5.5), withdrawn from the study, or who have completed the 26 week treatment period, but 
do not consent and/or are not eligible to participate in the 26 week extension study (Study 204682).
15. All visits will have a treatment window as in the table. Baseline (Week 0) serves as the reference point. Subjects will not be considered out of compliance if visit windows extend 
because of extraordinary events that make it impossible for subjects to complete a visit within the above window (e.g., holidays, vacations, personal emergencies). Determination 
of the maximum visit window deviation is at the discretion of the medical monitor
2014N210004_02 CONFIDENTIA L
[ADDRESS_484950]
ProcedureContinue Scheduled Clinic Visit 
(Weeks 4, 8, 12, 16, 20) 4, 5Week 26 
(Equivalent to End of Treatment 
Visit)Follow -up 
Week 34
Full (F) or brief (B) physical exam B F F
Weight X X X
12-lead ECG 1 X X
Vital S igns X X X
Clinical chemistry/hematology samples2 X X X
HbA1c and FPG 3 X X X
Review AE/SAE, concomitant medication and hypoglycemia 
eventsX X X
1. 12- lead ECGs will be obtained before measurement of vital signs and collection of blood samples for labor atory testing. Vital signs measurement will be taken before collection of 
blood samples. See Section 7.4.[ADDRESS_484951] be obtained.
Demo graph y and medical history  (including cardiovascular medical history /risk factors, 
T2DM history , history  of other prior and concomitant medical conditions, and substance 
usage) will be assessed at screening (as detailed in the eCRF).
Critical baseline asse ssments will include:  HbA 1c, FPG and immunogenicity.
Full details of screening and baseline assessments are provided in the Time and Events 
Table Section 7.1.
7.3. Efficacy
HbA 1cand FPG will be measured at the time points specified in the Time and Events 
Schedule in Section 7.1. Blood samples for HbA 1cand FPG should be collected before 
administration of study  treatment.
7.4. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1).  Unscheduled visits will occur as medically  necessary . Detailed procedures 
for obtaining each assessment are provided in the SRM.
7.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 5 .
The investigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
AEs and SAEs will be collected from the start of Study  Treatment until the follow -up 
contact (see Section [IP_ADDRESS] ), at the timepoints specified in the Time and Events Table 
(Section 7.1).
Medical occurrences that begin prior to the start of study  treatment but after obtaining 
informed consent may  be recorded on the Medical History /Current Medical Conditions 
section of the eCRF.
Any SAEs assessed as related to study  participation (e.g., protocol- mandated procedures, 
invasive tests, or change in existing therap y) or related to a [COMPANY_004] product will be recorded 
from the time a subject consents to participate in the study  up to and including an y 
follow -up contact. 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484952] has been discharged from the stud y, and he/she considers the event reasonabl y 
related to the stud y treatment or study participation , the investigator must promptly  notify  
[COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 5
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
“Have you taken an y new medicines, other than those provided in this study , since your 
last visit/contact?” 
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial A E/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs and non -serious AEs of special interest 
(as defined in Section 4.6.1 and Section [IP_ADDRESS] ) will be followed until resolution, until 
the condition stabilizes, until the event is otherwise explained, or until the subject is lost 
to follow -up (as defined in Section 5.5). Further information on follow -up procedures is 
given in Appendix 5 .
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in Appendix 5 and all deaths, w hether or not they  
are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non- cardiovascular death. 
The CV eCRF pages are presented as queries in response to reporting of certain CV 
(MedDRA) Medical Dictionary  for Regulatory  Activities terms. The CV information 
should be recorded in the specific cardiovascular section of the eCRF within one week of 
receipt of a CV Event data query
 prompting its completion. 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484953] be completed within one 
week of when the death is reported.
[IP_ADDRESS]. AEs of Special Interest
In the Phase IIIa clinical development program, AEs of special interest included several 
areas of safety  related concern for the T2DM population, particularl y for a GL P-1R 
agonist such as albiglutide.  
Specific eCRF page s will be used to capture additional details for the following AEs of 
special interest: 
Hypoglycemic events 
Liver events 
CV events (see Section [IP_ADDRESS] )
Injection site reactions 
Potential sy stemic allergic r eactions 
Pancreatitis 
MTC
Diabetic retinopath y 
Pneumonia 
Atrial fibrillation/atrial flutter 
The following additional AEs of special interest will be captured in the AE eCRF pages:
GI events
Pancreatic cancer 
Malignant neoplasms
Appendicitis
Subjects with drug h ypersensitivity  reactions that are not reasonabl y attributable to 
another cause or pancreatitis should discontinue investigational product and should not be 
rechallenged with albiglutide (see Section 5.5for complete list of AEs of special interest 
requiring withdrawal).
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_387059]-
serious AEs related to study  treatment (even for non- interventional post -marketing 
studies) is essential so that legal obligations and ethical responsibilities towards the safet y 
of subjects and the safet y of a product under clinical investigation are met. 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484954] (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessar y.
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requi rements.
7.4.2. Pregnancy
If a subject becomes pregnant during the stud y they should discontinue 
Investigational Product.
Any pregnancy  that occurs during stud y participation (i.e., from 
baseline/randomization through the end of the post- treatment follow -up perio d) 
must be reported using a clinical trial pregnancy  form.
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 weeks of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 6 .
7.4.3. Physical Exams
A full or brief ph ysical examination will be performed at the time points specified in the 
Time and Events Table Section 7.1
A full phy sical examination will include, at a minimum, assessment of the skin 
(including injection site), head, ey es, ears, nose, throat, thy roid, respi[INVESTIGATOR_387029] s ystem, abdomen (liver and spleen), ly mph nodes, central nervous 
system and extremities. 
Brief ph ysical examination includes evaluation of skin (including injection site), 
respi[INVESTIGATOR_36517], cardiovascular s ystem, abdomen (liver, spleen), and central 
nervous s ystem 
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses
Height will be measured and recorded at screening onl y. Height should be measured 
with the subject in indoor day time clothing with no shoes.
Weight will be measured at the time points specified in the Time and Events Table 
Section 7.1
Body mass index will be calculated at screening only .
2014N210004_02 CONFIDENTIA L
200952
547.4.4. Vital Signs
For vital signs (blood pressure and pulse rate), a single measurement will be taken at each 
clinic visit (Section 7.1). During visits when ECGs a re scheduled, vital sign 
measurements will be taken after the completion of the ECG sampling. Subjects may  be 
either in a semi -recumbent or seated position. During visits when ECGs are not 
scheduled, vital sign measurements will be taken while subjects are in a seated position 
after at least a [ADDRESS_484955] period. During visits where a blood draw is required, vital 
sign measurements will be taken prior to sample collection.
7.4.5. Electrocardiogram (ECG)
A single 12 -lead ECG recording (with subject in semirecumbe nt position for 10 to 
15minutes before obtaining the ECG) will be performed at the time points specified 
in the Time and Events Table (Section 7.1) using an ECG machine that automatically  
calculates the heart r ate and measures PR, QRS, QT, and QTc intervals.  Refer to 
Section 5.5.[ADDRESS_484956] compare the baseline ECG with the Visit 1 (screening) ECG. Any  
changes indicative of a new MI or unstable cardiovascular condition (i.e., life -threatening 
arrhythmia) should prompt the investigator to not administer the investiga tional 
product but rather to evaluate and treat the subject per local standard of care. If 
subsequent evaluation reveals that a new M I has occurred or unstable/accelerated angina 
is documented, then the subject will not be included in the study . If subsequ ent evaluation 
reveals no evidence of ischemic damage or instability , then study  treatment may  proceed. 
If any screening ECG demonstrates a possible old MI  that was unknown to the 
investigator and the subject, the subject should be evaluated and treated, a s appropriate. 
7.4.6. Clinical Safety  Laboratory  Assessments
All protocol required laboratory  assessments, as defined in Table [ADDRESS_484957] number, protocol number, site/centre number, and visit 
date. Details for the preparati on and shipment of samples will be provided by  [CONTACT_387060]. Reference ranges for all safet y 
parameters will be provided to the site by  [CONTACT_90633].
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorde d in the eCRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
2014N210004_02 CONFIDENTIA L
[ADDRESS_484958] be entered into the eCRF.
Hematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Table 6.
2014N210004_02 CONFIDENTIA L
200952
56Table 6 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count Red blood cell (RBC) 
Indices :White blood cell (WBC) count 
with Differential :
RBC Count mean corpuscular 
volume (MCV)Neutrophils
Hemoglobin mean corpuscular 
hemoglobin (MCH)Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1Blood urea 
nitrogen 
(BUN)Potassium Aspartate amino 
transferase (AST 
(SGOT))Total and direct 
bilirub in
Creatinine Sodium ALT (SGPT) Total Protein
Calcium chloride Alkaline phosphatise Albumin
bicarbonate Uric acid Gamma glutamyl 
transferase (GGT)
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic ex amination (if blood or protein is abnormal)
Other 
Laboratory
TestsHbA 1c
FPG
Amy lase2,5
Lipase2,5
HIV2
TSH2,3
Lipi[INVESTIGATOR_191273], LDL- C, HDL C, trigly cerides, 
FFAs (fasting)4
Hepatitis B (HBsAg)2
Hepatitis C (Hep C antibody )2
FSH and estradiol (as needed in women of non -child bearing 
potential only )
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])2
Serum  or urine hCG Pregnancy  test (as needed for women of c hild 
bearing potential) 
1. Details of Liver Chemistry Stoppi[INVESTIGATOR_131963] -Up Assessments after liver stoppi[INVESTIGATOR_103031] 5.5.4 and Appendix 3 .
2. Measured at screening only.
3. Free T4 (reflex) will be measured if TSH is above  the upper limit of normal
4. Fasting is defined as no food or drink (except water) for at least [ADDRESS_484959] dose of study  treatment 
should be repeated until the values return to normal or baseline.  If such values do not 
return to normal within a period judged reasonable by  [CONTACT_093], the etiology  
should be identified and the sponsor notified.
7.4.7. Estimated Glomerular Filtration Rate (eGFR)
Serum crea tinine will be measured at the time points specified in Time and Events 
Schedule in Section 7.1. It will be used to calculate eGFR using the MDRD formula 
[Leve y, 2009], name [INVESTIGATOR_31241]:
eGFR (ml/min/1.73m2) = 175 x (serum creatinine)-1.154x (Age)-0.203x (0.742 if female) x 
(1.212 if African American).
7.4.8. Diabetic Dietary , Exercise, and Home Plasma Glucose Monitoring 
Advice
Standard diabetic dietary, exercise, and home blood glucose mon itoring advice as well as 
on the signs and s ymptoms of hy poglycemia and on supplemental oral glucose treatment 
will be provided at Visit 2 (Week 0) and reinforced at each stud y site visit through the 
End of Treatment Visit (Week 26). Subjects should monito r the blood glucose as per the 
instructions of the investigator and as appropriate for their medical management. The 
subjects should report promptly , as directed by  [CONTACT_093], the occurrence of 
hypergly cemia or hy poglycemia (particularl y if s ymptoma tic) to the investigator (or his 
or her designee). Assessment and action should then occur as deemed appropriate b y the 
investigator.
7.4.9. Hypogl ycemic Events
Specific criteria for monitoring h ypogl ycemic events have been designed to ensure 
subject safet y and t o closely  monitor hy poglycemia. Hy pogly cemic events are defined as 
follows [ Seaquist , 2013]:
Severe Hypoglycemia
Severe h ypogl ycemia is an event requiring assistance of another person to activel y 
administer carboh ydrates, glucagon, or take other corrective actions. Plasma glucose 
concentrations may  not be available during an event, but neurological recovery  
following the return of plasma glucose to normal is considered sufficient evidence 
that the event was induced b y a low plasma glucose concentration. 
Documented Symptomatic Hypoglycemia
Documented s ymptomatic hy poglycemia is an event during which t ypi[INVESTIGATOR_387030]  a measured plasma glucose concentration 70 
mg/dL ( 3.9 mmol/L ). 
2014N210004_02 CONFIDENTIA L
200952
58Asymptomatic Hypoglycemia
Asymptomatic hy poglycemia is an event not accompanied by  [CONTACT_11017][INVESTIGATOR_78237] a measured plasma glucose concentration 70 mg/dL 
(3.9mmol/L). 
Probable Symptomatic Hypoglycemia
Probable sy mptomatic hypogl ycemia is an event during which sy mptoms t ypi[INVESTIGATOR_387031] b y a plasma glucose determination but that was 
presumabl y caused b y a plasma glucose concentration 70mg/dL ( 3.9mmol/L). 
Pseudohypoglycemia
Pseudohy poglycemia is an event du ring which the person with diabetes reports any  
of the ty pi[INVESTIGATOR_387032] a measured plasma glucose 
concentration >70 mg/dL (>3.9 mmol/L ) but approaching that level. 
Any hypoglycemic event, regardless of intensity, that satisfies the de finition of an SAE 
(Appendix 5 ) should be categorized as outlined in this section and reported appropriatel y 
in the SAE eCRF page and the hy poglycemic events AE of special interest page.
7.5. Tracking of A lbiglutide Ly ophil ized DCC Pen Injector and 
Liquid A uto-injector Failures and User Errors
All albiglutide ly ophilized product DCC pen injector and liquid product auto -injector 
failures and user errors must be detected, documented, and reported b y the investigator 
throughout the study . Detailed information on DCC pen injector and auto -injector failures 
and user errors will be collected on the Injector Pen and Auto- injector Failure Reporting 
Form.
NOTE: Albiglutide l yophilized DCC pen injector and liquid auto -injector failures and 
user errors associated with or resulting in events fulfilling the definition of an AE or SAE 
will follow the processes outlined in Section 7.4.1 .
7.6. Pharmacokinetics
7.6.1. Blood Sample Collection
Blood samples for t he determination of albiglutide plasma concentrations will be 
obtained from all subjects before administration of study  treatment according to the Time 
and Events Table in Section 7.1.During visits where ECGs an d vital sign measurements 
are required, blood samples will be collected after measurement of ECGs and vital signs.
Blood samples will be collected and stored as detailed in the L aboratory  Manual.
2014N210004_02 CONFIDENTIA L
200952
597.6.2. Sample A nalysis
Plasma analy sis will be performed under the control of PTS -DMPK, GlaxoSmithKline, 
the details of which will be included in the Study  Reference Manual (SRM). 
Concentrations of albiglutide will be determined in plasma samples using the currently  
approved bioanaly tical methodology . Raw data will be arc hived at the bioanaly tical site 
(detailed in the SRM).
Once the plasma has been anal yzed for albiglutide, any  remaining plasma may  be 
analyzed for other compound -related metabolites and the results reported under a 
separate PTS -DMPK, GlaxoSmithKline protoc ol.
7.7. Immunogenicity
Serum for antidrug antibody  testing will be obtained from all subjects before 
administration of study  treatment  at week 0, 2, 4, 8, 12, 16, 20, 24, 26 and at follow -
up(wk 34, if applicable),according to the Time and Events Table in Sect ion 7.1
The presence of anti -albiglutide antibodies will be assessed using a validated enzy me-
linked immunosorbent assay . The assay  involves screening, confirmation, and titration 
steps (tiered- testing approach ). Confirmed positive samples will be titrated to obtain the 
titre of antibodies and tested for GLP -1 and albumin cross -reactivity , as well as for 
albiglutide neutralizing activity . Samples positive for both anti -GLP -1 antibodies and 
drug neutralizing anti bodies may  be tested for GLP -1 neutralizing activity  (Appendix 7 ).
Additionally , in the case of severe allergic reactions that include anaphy laxis, 
angioedema, or other severe potential h ypersensitivity  reactions, thre e 1-mL serum 
samples should be obtained for immunogenicit y testing (within 24 hours of the event if 
possible) and sent to the central  laboratory  (see details in the SRM) for immediate 
distribution to a contracted testing facility  for specific immunologica l testing (albiglutide -
specific IgE and other tests, as appropriate)  A follow- up serum sample will be collected 
[ADDRESS_484960] completed the 
26 week treatment period, but do not consent and/or are not eligible to participate in the 
26 week extension study  (Study  204682), if baseline antibody  levels or a reduction in 
titer are not achieved b y the follow -up visit then additional samples for immunogenicit y 
testing may  be obtained every  30 day s following the follow -up visit until baseline 
antibody  levels, or reduced titres, are achieved. Subjects eligible for the extension study  
(Study  204682) will have immuno genicit y samples taken as specified in protocol 204682.
7.8. Genetics
Information regarding genetic research is included in Appendix [ADDRESS_484961] data will be entered via an eCRF into Oracle Clinical Remote Data 
Capture (OC RDC) s ystem. Subject data will be available for viewing through access to 
the OC RDC sy stem. Data provided from other sources will be received, reconciled, 
combined and transferred to [COMPANY_004] at predetermined time points.
Managem ent of clinical data will be performed in accordance with applicable [COMPANY_003] 
standards and data cleaning procedures to ensure the integrity and quality of the data, 
e.g., removing errors and inconsistencies in the data. Adverse events and concomitant 
medicatio n terms will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA) and a validated medication dictionary  [COMPANY_004]Drug.
The eCRFs (including queries and audit trails) will be sent at the end of the study  in CD 
format to [COMPANY_004] to be retained. Eac h investigator will receive a copy  of their site specific 
data in the same format to maintain as the investigator copy. In all cases, subject initials 
will not be collected or transmitted.
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary hypothesis is to test that liquid drug product will provide gly cemic control 
(as measured b y HbA1c change from baseline) non -inferior to l yophilized drug product 
for a period of [ADDRESS_484962] e Size A ssumptions
This study  will randomly assign approximately  150 subjects to each of the 2 treatment 
groups (liquid drug product and ly ophilized drug product) in a 1:1 ratio, for a total of 
approximately  300 subjects. Eligible subjects will be stratifi ed by [CONTACT_654] (<65 or ≥65 y ears 
of age), weight (<90 kg or ≥90 kg), and background antidiabetic therap y (diet and 
exercise or stable dose of metformin).  
With 133 subjects in each of the 2 treatment groups, the study  will provide 90% power to 
demonstrate non -inferiority  for HbA1c change from baseline, assuming a non -inferiorit y 
margin of 0.4%, an expected treatment group difference of 0.0%, and a common standard 
deviation of 1%, using a 2- sample, [ADDRESS_484963] with significance level of 0.025. Power 
was calcu lated using PASS [ Hintze , 2013]. Assuming that 13% of subjects will be 
withdrawn earl y or will be lost to follow -up; therefore, approximately  [ADDRESS_484964] as active control. Results from two HARMONY 
2014N210004_02 CONFIDENTIA L
200952
61Phase III studies (subset of GL P112756 and GLP112753) for the comparison of the 
control albiglutide l yophili zed drug product versus placebo were used in selecting the 
non-inferiorit y margin. The two studies are similar to the current stud y in terms of the 
population and the design; subjects were either on diet and exercise or metformin 
background therap y and rec eived 30 mg of albiglutide then up -titrated to 50 mg 
albiglutide. The 95% confidence interval from the [ADDRESS_484965] difference from placebo 
is ( -1.04, - 0.75). The conservative effect in terms of the difference from placebo for 
HbA1c change from baseline at Week [ADDRESS_484966] versus 
placebo is 0.75% (M1 =0.75%, as defined in Guidance for Industry : Non -Inferiorit y 
Clinical Trials [ FDA , 2010]).  M2, calculated as 50% of M1 is 0.375 (approximately  0.4). 
The margin of 0.40% that should be met in this trial will preserve at least 45% of the 
effect of the comparator and it is below M1.
9.2.2. Sample Size Sensitivity
Figure [ADDRESS_484967] the null h ypothesis of inferiority for HbA1c change from baseline, assuming a 
non-inferiorit y margin of 0.4%, an expected treatment group difference of 0.0%, and a 
sample size of [ADDRESS_484968] Deviations (S1) of 0.7, 0.8, 0.9, 1.0, 1.1, and 1.2
9.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation is planned for this study .
2014N210004_02 CONFIDENTIA L
200952
629.3. Data Analysis Considerations
9.3.1. Analysis Populations
Intent -to-Treat (ITT) Population :  The I TT Po pulation will include all randomized 
subjects who receive at least [ADDRESS_484969] a baseline 
assessment. The ITT population will be analy zed according to the randomly  assigned 
treatment. The ITT Population is the primary  population for all efficacy  analy ses.
Safety Population:   The Safety  Population is defined as all enrolled subjects who receive 
at least 1 dose of stud y medication. The subjects in the Safet y Population will be 
analyzed according to the treatment received. The Safet y Population will be used for all 
safet y analyses.
Per-Protocol (PP) Population : The PP Population will include all subjects randomly 
assigned to treatment who complete study  procedures through Week 26 and are 
compliant with the protocol. The subjects in t he PP Population will be analy zed 
according to randomized treatment. The PP Populations may be used for supportive 
analyses of the efficacy  endpoints.
Other anal ysis populations will be defined in the reporting and anal ysis plan (RAP).
9.3.2. Interim A nalysis
No interim anal ysis is planned for this study .
9.4. Key Elements of A nalysis Plan
9.4.1. Primary  Analyses
The primary  endpoint is the change from baseline in HbA1c at Week 26. The primary  
analysis will include all HbA1c values collected at scheduled visits up to Week 26. This 
will include values after hy pergly cemia rescue and discontinuation from investigational 
product. The primary  analy sis of the primary  endpoint will be conducted using a mixed -
effect model with repeated measures (MMRM) in the ITT Population. MMRM will use 
all available data.  Imputation under the non -inferiority  null hy pothesis for missing data 
will be incorporated [ Koch , 2008]. Multiple imputation will be used to replace missing 
data of change from baseline of HbA1c at Week [ADDRESS_484970] -baseline 
visits as dependent variables; treatment, region, age category , weight, background 
antidi abetic therap y, visit week, and treatment- by-week interaction as fixed effects; 
baseline HbA1c as a continuous covariate; and subject as a random effect. Treatment 
effects estimates (and associated CI) of albiglutide liquid drug product will be evaluated 
within this MMRM model as least squares means contrasts relative to the lyophilized 
drug product. An unstructured covariance matrix will be used for the MMRM analy sis, 
unless the model does not converge, in which case the covariance matrix will be decided 
upon model convergence status and the Akaike information criterion. 
9.4.2. Secondary  Analyses
The evaluation of the safety  and tolerability  as assessed by  [CONTACT_387048] I SRs of 
albiglutide liquid drug product and the l yophilized drug product will be provided by 
[CONTACT_387049], and the associated 95% CI .
The overall general safety and tolerability  of albiglutide liquid drug product versus 
lyophilized drug product will be evaluated in tabular and/or graphical format and 
summarized descriptively. 
AEs and SAEs, phy sical examinations, clinical laboratory  evaluations, vital sign 
measurements, and [ADDRESS_484971] devi ation (and/or standard error), minimum, and maximum. For categorical 
variables, the summaries will include frequencies and corresponding percentages. The 
exposure -adjusted incidence rate will also be calculated as the number of events in a 
given period div ided b y the total person time on treatment of subjects at risk within the 
same period. The exposure- adjusted incidence rate will be expressed as an annualized 
rate expected.  No inferential testing will be performed on the safety  variables. 
Hypoglycemic ev ents will be anal yzed separately from other AEs. All h ypogl ycemic 
events will be classified as severe, documented s ymptomatic, asymptomatic, probable 
symptomatic, and pseudohy poglycemia, as defined in Section 7.4.9 .
AEs will be coded using MedDRA. AEs will be summarized in various subsets, including 
on therap y AEs, related AEs, AEs leading to treatment discontinuation or withdrawal 
from study , SAEs, fatal AEs, etc. AEs will also be summarized by  [CONTACT_11196]
(mild, moderate, and severe).
Anti- albiglutide antibod y results will be summarized by [CONTACT_1570]. In addition, the 
number and percentage of subjects with positive results along with the antibody  titer 
values will be provided by [CONTACT_765]. 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484972] -
baseline visits as dependent variables; treatment, visit week, and treatment -by-week 
interaction as fixed effects; baseline HbA1c or FPG as a continuous covariate; a nd 
subject as a random effect. Treatment effects estimates (and associated CI) of albiglutide 
liquid drug product will be evaluated within this MMRM model as least squares means 
contrasts relative to the lyophilized drug product. An unstructured covariance matrix will 
be used for the MMRM analy sis, unless the model does not converge, in which case the 
covariance matrix will be decided upon model convergence status and the Akaike 
information criterion. In addition, PD effect of albiglutide over time for both HbA1c and 
FPG change from baseline over time will be evaluated in tabular and/or graphical format 
and summarized descriptively .
PK trough plasma concentration data will be summarized by  [CONTACT_3148]. No formal 
statistical analy ses will be conducted.
9.4.3. Other A nalyses
The anal yses of the primary  and secondary  efficacy  endpoints are described in Section 
9.4.1 and Section 9.4.2 . The details of an y further planned anal yses, inc luding subgroup 
analysis and exploratory  endpoints, will be provided in the RAP.
9.4.4. Supportive A nalyses for Primary  Endpoint
The primary  endpoint change from baseline in HbA1c at Week 26 will be analy zed using 
the same MMRM model as described in S ection 9.4.1 but missing data are not explicitly  
imputed in this supportive anal ysis; although, there is an underl ying assumption that data 
is missing at random. All available scheduled post -baseline assessments up to endpo int 
are utilized and, via modeling of the within subject correlation structure, the derived 
treatment difference at Week 26 is adjusted to take into account missing data. The 
MMRM analy sis (using saturated fixed effects and an unstructured variance -covaria nce 
matrix) is considered appropriate as the supportive anal yses, as it has been shown to give 
sensible answers to on- treatment questions in a range of practical situations [ Siddiqui , 
2009].
Analy sis excluding post
-rescue and/or discontinuation from investigational product 
HbA1c data will also be performed as supportive.  I t is not expected to have a substantial 
number of subjects who will require rescue and that number of subjects would be similar 
for both treatment arms.  However, to assess the impact of rescue, anal ysis of pre -rescue 
data will be performed. The MMRM model will be similar to the one used for the 
primary  anal ysis.  Results of this analy sis will supplement the primary  analy sis. No 
imputation will be c onducted for this supportive analy sis.
2014N210004_02 CONFIDENTIA L
200952
65The primary  endpoint HbA1c change from baseline at Week 26 may  also be anal yzed 
using MMRM model in the PP Population, if sample size is sufficient, imputation will 
not be conducted for this supportive anal ysis. 
Further details of the supportive anal yses will be provided in the RAP.
9.4.5. Missing Data
[IP_ADDRESS]. Impact of Missing Data on Primary  Endpoint
Missing data, in the context of the primary  anal ysis at Week 26, refer to those cases 
where the Week [ADDRESS_484973] of 
missing data on th e primary  endpoint to be minimal. I mputation under the non- inferiorit y 
null hy pothesis [ Koch , 2008] for all missing data for the primary  anal ysis at Week 26 will 
be implemented.
[IP_ADDRESS]. Extent of Missing Primary  Analysis Data
Missing data is expected to arise mainly from subjects missing complete visits. The 
amount of missing data for those baseline covariates included in the statistical anal ysis is 
expected to be none or at worst minimal. I f it should occur, that subject will e ffectivel y 
be lost to analy sis. Missing data for HbA1c between two non -missing visits will be 
considered missing at random (intermediate missing data).
In this stud y, subjects who withdraw from treatment will stay  in the study . In the eCRF, 
the reason for treatment discontinuation and the reason for withdrawal from the study  are 
collected separatel y. Whenever the HbA1c value at Week 26 is missing (end of the 
study ), the reason can be determined based on available data in these two locations.
The reason for 
missing data can be classified as lost to follow -up or withdrawal of 
consent.
[IP_ADDRESS]. Reasons for Withdrawal
Reasons for withdrawal from the study  are lost to follow -up or withdrawal consent.  All 
subjects who discontinuation from investigational product due to th e reasons listed under 
Section 5.5will remain in the study  and efficacy  and safet y data will be collected.
[IP_ADDRESS]. Handling of Missing Data
The impact of missing data will be explored, as outlined below, for the ITT An alysis 
Population only .
2014N210004_02 CONFIDENTIA L
[ADDRESS_484974] to follow -up or withdrawal consent, 
cohorts of subjects will be defined based on the scheduled assessments (HbA1c change 
from baseline) that were completed at Weeks 1, 4, 8, 12, 16, 20, and 26.
Subjects who have week 1 assessment only
Subjects who have assessments up to and including Week 4 onl y
Subjects who have assessments up to and including Week 8 onl y
Subjects who have assessments up to and including Week 12 onl y
Subjects who have assessments up to and including Week 16 onl y
Subject s who have assessments up to and including Week 20 onl y
Subjects who have assessments up to and including Week 26.
The number and percentage of subjects on each treatment in the [ADDRESS_484975] and stay ed in 
the study ; exclusion of data after treatment discontinuation may  also be performed if a 
significant number of subjects discontinue study  medication prior to Week 26. On 
treatment data will be analy zed using MMRM model as described in Section 9.4.1 .  
Week 26 observations off -treatment will be imputed under the non -inferiority  null 
hypothesis [ Koch , 2008].
Sensitivity  analy ses using a different ty pe of multiple imputation method will be 
conducted. Firstly , missing data between two non- missing t
ime points will be considered 
missing at random (MAR). The anal yses using the last mean carried forward (LMCF) 
approach will be performed using the following rates of HbA1c increase: 0%/month, 
0.1%/month, and 0.2%/month to explore the potential impact as i n a tippi[INVESTIGATOR_007] -point 
analysis. For each treatment group, these [ADDRESS_484976] multiple imputation rules.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favorable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH (International 
Conference on Harmonization) Good Clinical Practice (GCP) and applicable country -
specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH GCP, all applicable subject 
privacy  requirements, and the guiding principles of the current version of the Declaration 
of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Investigator reporting requirements (e.g. reporting of AEs/SAEs/ protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation in 
the study  (and for amendments as applicable).
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and th e clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.   In this situation, written 
approval of the clinical protocol should state that approval of optional assessments 
is being deferred and the study , with the exception of the optional assessments, can 
be initiated.
2014N210004_02 CONFIDENTIA L
[PHONE_8067].3. Qualit y Control (Study  Monitoring)
In accor dance with applicable regulations including good clinical practice (GCP), 
and [COMPANY_004] procedures, [COMPANY_004] monitors will contact [CONTACT_387061], study  requirements, and their 
responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF will 
serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study agreements, GCP, and a ll applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regula tory requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, audit o r inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any finding s/relevant issues and to implement any  
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more or 
at all sites.  
If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with t he investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
2014N210004_02 CONFIDENTIA L
200952
69investigator or the head of the medical institution, where applicable, of the 
impending action.
If the stud y is suspende d or prematurely  discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for those 
required b y loca l regulations to be maintained elsewhere), in a safe and secure 
location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for review in 
conjunction with assessment of the facility , supporting s ystems, and relevant site 
staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, elect ronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -gene rating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of ownership 
of the reco rds in the event the investigator is no longer associated with the site.
2014N210004_02 CONFIDENTIA L
[PHONE_8068].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requireme nts, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] w ill provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
10.8. Review  Committees
A PAC composed of independent specialists in gastroenterology  will review cases of 
possible pancreatitis. Details of this committee and case adjudication will be described in 
a separate charter.
2014N210004_02 CONFIDENTIA L
[PHONE_8069]. REFERENC ES
American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. 
Diabetes Care, 2014; 37 (Suppl 1): S81- S90.
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT. Pancreatic safety  of incretin -
based drugs —FDA and EMA assessment. N Engl J Med. 2014; 370(9):794-7. 
European Public Assessment Report (EPAR) for Eperzan. 2014. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/[ZIP_CODE]
5/human_med_001735.jsp&mid=WC0b01ac058001d124
FDA Summary  Basis of A pproval. 2014. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000TOC.cfm
Food and Drug Administration (FDA). Guidance for Industry . Non- Inferiority  Clinical 
Trials. U.S. Department of Health and Human Services. Food and Dr ug Administration. 
Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and 
Research (CBER). March 2010 Clinical/Medical. Available from: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM202140.pdf (Accessed 12 Apr 2015).
Gautier JF, Fetita S, Sobngwi E and Salaun- Martin C. Biological actions of the incretins 
GIP and GL P-1 and therapeutic perspectives in patients with ty pe 2 diabetes. Diabetes 
Metab. 2005; 31(3 Pt 1):233-42.
Hintze, J. PASS 1 2. NCSS, LLC. Kaysville, Utah, [LOCATION_003]. 2013. Available at 
http://www.ncss.com.
Khunti K, Andersen M, Wolden ML , Davies MJ and Thorsted BL. Clinical I nertia in 
People With Ty pe 2 Diabetes. Diabetes Care. 2013; 36:3411-3417
Koch, G.Comments on ‘Current issues in non -inferiorit y trials’. Statistics in Medicine. 
2008; 27: 333-342
Levey  AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate.  Ann I ntern Med. 2009; 150: [ADDRESS_484977] ER, Anderson J, Childs B, Cry er P, Dagogo- Jack S, Fish L, et al. Hy poglycemia 
and diabetes:  a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013; 36:1384 -95.
Siddiqui O, Hung HM, O’Neill R. MMRM vs. LOCF: a compre hensive comparison 
based on simulation study  and 25 NDA datasets. J Biopharm Stat. 2009;19 (2):227 -46.
World Health Organization (WHO). Diabetes Fact Sheet. October 2013. Available at 
http://www.who.int/mediacentre/factsheets/fs312/en/ (Accessed Nov20, 201 4).
2014N210004_02 CONFIDENTIA L
[PHONE_8070]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
ADA American Diabetes Association
AE adverse event
ALT (SGPT) alanine aminotransferase (serum glutamic p yruvic 
transaminase)
AST (SGOT) aspartate aminotransferase (serum glutamic oxa loacetic 
transaminase)
BMI body  mass index
BUN blood urea nitrogen
CI confidence interval
CONSORT Consolidated Standards of Reporting Trials
CPK creatine phosphokinase
CV cardiovascular
DCC dual chamber cartridge
DNA deox yribonucleic acid
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
ELISA enzy me-linked immunosorbent assay
EMA European Medicines Agency
FDA US Food and Drug Administration
FFA free fatt y acids
FPG fasting plasma glucose
FRP females of reproductive potential
FSH follicle stimulating hormone
GCP Good Clinical Practice
GCSP Global Clinical Safety  and Pharmacovigilance
GGT gamma glutam yl transferase
GI gastrointestinal
GLP-[ADDRESS_484978] acement therapy
IB Investigator’s Brochure
ICH International Conference on Harmonization
2014N210004_02 CONFIDENTIA L
[ADDRESS_484979]
ISRs injection site reactions
ITT intent-to-treat
IVRS Interactive Voice Response Sy stem
LDH lactate deh ydrogenase
LDL -c low density  lipoproteins; 
LMCF last mean carried forward
K2EDTA di-potassium ethy lenediaminetetraacetic acid
MACE major adverse cardiovascular event
MAR missing at random
MCH mean corpuscular hemoglobin
MCV mean corpuscular volume
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary  for Regulatory  Activities
MEN-[ADDRESS_484980] upper limit of normal range
WBC white blood cell
WCBP women of child bearing potential
2014N210004_02 CONFIDENTIA L
200952
74Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_387062]
2014N210004_02 CONFIDENTIA L
[PHONE_8071].2. Appendix 2: [COMPANY_004] Modified List of Highly  Effective Methods 
for Avoiding Pregnancy  in Females of Reproductive 
Potential (FRP)
19.Contraceptive subdermal i mplant that meets effectiveness criteria including a <1% 
rate of failure per year, as stated in the product label.
20.Intrauterine device or intrauterine s ystem that meets effectiveness criteria including a 
<1% rate of failure per year, as stated in the produ ct label [ Trussell , 2011]
21.Oral Contraceptive, either combined or progestogen alone [ Trussell , 2011] 
22.Injectable progestogen [ Trussell , 2011]
23.Contraceptive vaginal ring [ Trussell , 2011]
24.Percutaneous contraceptive patches [ Trussell , 2011]
25. Male partner sterilization prior to the female subject's entry into th e stud y, and this 
male is the sole partner for that subject. The information on the male sterility  can 
come from interview with the subject on her male partner’s medical history .
26.Male condom 
combined with a female diaphragm, with or without a vaginal 
sperm icide (foam, gel, film, cream, or suppository).
These allowed methods of contraception have a failure rate of less than 1% per year but 
are onl y effective when used consistently, correctly and in accordance with the product 
label.  The investigator is resp onsible for ensuring that subjects understand how to 
properl y use these methods of contraception.
References
Trussell J, Contraceptive Efficacy . In: Hatcher RA, Trussell J, Nelson AL , Cates W, 
Kowal D, and Policar M (editors). Contraceptive Technology : Twe ntieth Revised 
Edition. [LOCATION_001]: Ardent Media, 2011.Table 26 -1
2014N210004_02 CONFIDENTIA L
[PHONE_8072].3. Appendix 3: Liver Safety  Required A ctions and Follow up 
Assessments
Phase III -IV liver chemistry stoppi[INVESTIGATOR_301131] y and eva luate liver event etiology  (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Phase III -IV liver chemistry stoppi[INVESTIGATOR_387033] - Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for  4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatme nt 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event eCRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resol ve , stabilize, or return to within baseline 
(see MONITORING below)Viral hepatitis serology4
Only in those with underlying chronic 
hepatitis B at study entry (identified by 
[CONTACT_95570] h epatitis B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for PK analysis, obtained 
within 3 half -lives (15 days) after last dose6
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
2014N210004_02 CONFIDENTIA L
200952
77Liver Chemistry Stoppi[INVESTIGATOR_2121] - Liver Stoppi[INVESTIGATOR_53056]
Do not restart/rechallenge subject with 
study treatment 
If restart/rechallenge not  allowed or not 
granted , permanently discontinue study 
treatment and may continue subject in the 
study f or any protocol specified follow up 
assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24 
hrs
Monitor subjects twice w eekly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver eve nt follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baselineFractionate bi lirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smoo th muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adducts HPLC 
assay (quantifies potential acetaminophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]). NOTE: 
not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy eCRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury.
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
2014N210004_02 CONFIDENTIA L
200952
78studies of hepatic impairment or cirrhosis) ; INR measurement is no t required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or beli eved to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
ribonucleic acid (RNA); Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if 
unavailable, obtain heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of s tudy treatment prior to 
blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].  
Phase III -IV liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  5xULN and <8xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 2 weeks.
OR
ALT  3xULN and <5xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeks.Notify the [COMPANY_004] medical monitor within [ADDRESS_484981] 
safety. 
Subject can continue study treatment 
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If ALT d ecreases from ALT 5xULN and <8xULN 
to ≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
2014N210004_02 CONFIDENTIA L
[ADDRESS_484982] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363–2369. 
2014N210004_02 CONFIDENTIA L
[PHONE_8073].4. Appendix 4: Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including an y treatment regimens under inves tigation in 
this study  or any  concomitant medicines;
T2DM susceptibility , severity , and progression and related conditions.
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include foc used candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be document ed in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropr iate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in dise ase and medicine response.  
A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. A blood 
sample is collected at the baseline visit, after the subject has been randomized and 
provided informed consent for genetic research. Instruct ions for collection and shippi[INVESTIGATOR_387034]. The DNA from the blood 
sample may  undergo quality  control anal yses to confirm the integrity  of the sample. If 
there are concerns regarding the qualit y of the sam ple, then the sample may  be destroy ed. 
The blood sample is taken on a single occasion unless a duplicate sample is required due 
to an inability  to utilize the original sample.  
The genetic sample is labeled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study.   This number can be traced or linked back to 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484983] by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stor ed securel y and may be kept for up to [ADDRESS_484984] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subje cts who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic re search in which case the genetic DNA sample is 
retained
Discontinue participation in the genetic research and destroy  the genetic DNA sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigato r must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at th e time of withdrawn consent will continue to be 
stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
2014N210004_02 CONFIDENTIA L
[ADDRESS_484985]’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish th e results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual g enoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefor e the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
2014N210004_02 CONFIDENTIA L
[PHONE_8074].5. Appendix 5: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporally associated with the use of a medicinal product, whe ther or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgment of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New c onditions detected or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequ elae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfill the definition
of an AE or SAE.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
2014N210004_02 CONFIDENTIA L
200952
84condition.
Medical or surgical proce dure (e.g., endoscopy , appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threat ening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have be en appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_23919], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The te rm disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
2014N210004_02 CONFIDENTIA L
200952
85This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_387035] l intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronch ospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.5.3. Definition of Cardiov ascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the eCRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
2014N210004_02 CONFIDENTIA L
200952
86Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.5.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the eCRF
Itis notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE eCRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this i nstance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  I n such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
12.5.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event ; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
2014N210004_02 CONFIDENTIA L
200952
87Assessment of Causality
The investigator is obligated to assess the rela tionship between study  treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/s he 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool according ly.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examination s or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
2014N210004_02 CONFIDENTIA L
[PHONE_8075].5.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor or the SAE 
coordinator
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor or the SAE coordinator by [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
2014N210004_02 CONFIDENTIA L
[PHONE_8076].6. Appendix 6: Collection of P regnancy  Information
Pregnancy information on female study subjects 
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and subm itted to [COMPANY_004] within [ADDRESS_484986]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The investigator 
will collect follow up information on mother and infant, which will be forwarded to 
[COMPANY_004].  Generally , follow- up will not be required for longer than 6 to 8 weeks bey ond 
the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, an y pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result o f a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_387063] [ADDRESS_484987] who becomes pregnant while participating 
Will discontinue study  medication.
2014N210004_02 CONFIDENTIA L
[PHONE_8077].7. Appendix 7: Immunogenicity  Testing Algorithm
The immunogenicit y of albiglutide will be evaluated using the following testing schemes 
and assay s.
Sample Testing Schemes
Samples for immunogenicity  testing will be obtained as detailed in the time and events 
schedule (Section 7.1) and Section 7.7.
The presence of anti -albiglutide antibodies will be assessed using a validated screening 
enzy me-linked immunosorbent assay  (ELISA).  If serum samples contain anti -albiglutide 
antibodies, they  will be further analyzed in a confirmation assay  to show specificit y for 
albiglutide.  Confirmed positive samples will be titrated to obtain the anti -albiglutide titer 
value.  To test whether anti -albiglutide antibodies cross -react with endogen ous glucagon-
like peptide (GLP -1) or human albumin (HA), positive samples will be tested in 
secondary  assay s which include anti -GLP -1or anti -HA screening ELISA’s, respectivel y.  
In addition, anti- albiglutide positive samples will be tested for neutralizing activity  
against the drug in a cell- based assay .  Subjects that are positive for anti -albiglutide 
neutralizing antibodies and anti- GLP-[ADDRESS_484988] GLP-1.
Antib ody Detection Assays
The detection assay s are ELISA- based and utilize a tiered testing approach.  The anti-
albiglutide assay  includes screening, confirmation and titration assay s. The anti -GLP-1 
ELISA includes screening and confirmation steps.  For the an ti-HA ELISA only  a 
screening step is feasible.
The procedure for the albiglutide immunoglobulin (IgG/A/M) ELISA is described below :
1. 96 -well ELISA plates are coated with albiglutide overnight.
2. Samples are diluted 1:50 and incubated on blocked plates for 3 hours.
3. A horseradish peroxidase (HRP)- labeled anti -human IgG/A/M antibod y is used as 
the detection antibod y.
4.A tetrameth ylbenzidine peroxidase substrate is used to produce the enz ymatic 
reaction which is followed by  [CONTACT_387064]. 
5.The plates are read at 450 nm using a SpectraMax Plus 384 reader (Molecular 
Devices LLC, Sunn yvale, [LOCATION_004]), or the equivalent.
6. A positive control (normal human serum pool spi[INVESTIGATOR_387036]- human GLP -1 
antibody ) and negative control (pooled normal human serum) are inc luded on 
each assay  plate.
7.Relative optical density  values are calculated by  [CONTACT_387065].
2014N210004_02 CONFIDENTIA L
200952
91Screening
Screening comprises determination of a cutoff value for drug- naïve T2DM subjects and 
identification of serum samples potentially  positive for anti -albiglutide antibody .
Confirmation
Specificity  of serum antibodies is confirmed by  [CONTACT_387066].  I f the sample is still positive 
after the confirmation assay , the sample will be reported as positive and further anal ysis 
will be done by  [CONTACT_387067] s.
Titration
Confirmed po sitive samples will be titrated to obtain a titer  value of anti -albiglutide 
antibody .
Neutralizing Antibody Assays
The neutralizing antibody assay s are cell -based reporter gene assay s, which include 
screening, confirmation and titration assay s.  Albigluti de-neutralizing activity  is 
measured b y adding serum samples pre- incubated with a fixed concentration of 
albiglutide to GL P-1 receptor/CRE (cy clic adenosine monophosphate response element)-
luciferase transfected cells and measuring luminescence intensity  after 3 hours of 
incubation.  Samples possessing neutralizing activity  will generate a reduced signal and 
will be further tested in confirmation (specificit y) assay  if the generated signal is positive 
(i.e., below the assay ’s screening cutoff).  Confirmed p ositive samples will be titrated to 
obtain a titer value of neutralizing anti- albiglutide antibody .
Immunogenicity Testing Report
The immunogenicit y testing report will include the incidence of immunogenicity , 
incidence of neutralizing antibodies and the a ntibody  titers (binding and neutralization to 
albiglutide).  Cross -reactive antibodies to GL P-1 and HA will be discussed.
2014N210004_02 CONFIDENTIA L
[PHONE_8078].8. Appendix 8: Country  Specific Requirements
No country -specific requirements exist.
2014N210004_02 CONFIDENTIA L
[PHONE_8079].9. Appendix 9: Protocol A mendment Changes
Changes Res ulting from Protocol A mendment 1
This amendment is applicable to all participating countries.
Summary  of Changes
1.Benefit risk table modified to provide further details relating to mitigation 
strategies.
2.Exclusion criteria related to abnormal TSH modified.
3.Exclusion criteria numbering corrected. Exclusion criteria for ‘fasting trigl yceride 
level >750 mg/dL at screening’ was un -numbered and formed part of exclusion 
criteria 14. 
4. Exclusion criteria relating to positive urine drug screen result at Screening 
modified.
5.New text to clarify  visit windows.
6. Time and Event Table modified to add HbA1c sample at Week [ADDRESS_484989] of Specific Changes
Amendment 1:
Section 4.6.1, Table 2, Risk Assessment for Albiglutide
Original text:
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Pancreatiti s Acute pancreatitis has been reported in association with albiglutide and other 
GLP-1 receptor agonists in clinical trials and during postmarketing experience.
Albiglutide has not been studied in subjects with a history of pancreatitis to 
determine whethe r they are at increased risk for pancreatitis.Subjects with a history of acute or chronic pancreatitis are 
excluded from entering the study (See Section 5.2).
Subjects will be informed of the characteristic symptom of 
pancreatitis: persistent severe abdom inal pain. If 
pancreatitis is suspected, albiglutide should be promptly 
discontinued and if pancreatitis is confirmed, study 
treatment will not be restarted (see Section 5.5).
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Gastrointestinal (GI) events. Albiglutide has not been studied in subjects with severe GI disease, including 
severe gastroparesis. 
Use of albiglutide can be associated with GI side effects such as diarrhea, 
nausea, and vomiting.Subjects with severe gastroparesis are excluded from 
entering the study (See Section 5.2).
Subjects with a history of significant GI surgery that in the 
opi[INVESTIGATOR_387037] n  are excluded from 
entering the study (See Section 5.2).
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Hypoglycemia. Albiglutide’s mechanism of action is associated with a low intrins ic risk of 
significant hypoglycemia when used as monotherapy or in combination with 
agents such as metformin which also have low intrinsic risk for significant All subjects are required to have a last indicator of 
glycemic control of above HbA 1c= 7% which is 
expected to reduce the risk of hypoglycemia when 
2014N210004_02 CONFIDENTIA L
200952
95Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
hypoglycemia . starting albiglutide. 
Subjects are neither allowed to use insulin nor insulin 
secretagogues during the study. Except as part of 
hyperglycemia rescue (see Section 5.4)
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Immunogenicity 
(e.g., including anti- drug antibodies, 
clinical sequelae of antidrug 
antibodies, severe hypersensitivity 
reactions, and other potential 
immune -related AEs).Hypersensitivity reactions are of potential concern with any injected 
protein and were reported rarely in the Phase III program with lyophilized 
albiglutide. In the Phase III program one subject (anti -albiglutide antibody 
negative) developed rash and itching; and upon rechallenge recurrence of 
these symptoms associated with dyspnea. 
Risk assessment of the albiglutide molecule predicted low immunogenic 
potential, which was substantiated for the commercial lyophilized DCC pen 
injector product in the registration program. Treatment -emergent anti- drug 
antibodies were detected in ~5 % subjects over studies of up to 3 years duration 
and were generally transient, of low titer, and not neutralizing.
Subjects who tested positive for anti -albiglutide an tibodies experienced a similar 
glycemic response (HbA1c and fasting plasma glucose) to those who did not 
test positive for antibodies. Other than injection site reactions (see below), the 
overall safety profile appeared similar among the subset of subjects who did 
and those who did not test positive for anti -albiglutide antibodies. 
Changes in the propensity of the liquid product to form aggregates could have 
an impact on anti- drug antibody characteristics or immune related AEs.  
However, the likelihood of clinically important changes in anti -drug antibody 
characteristics or immune related AEs with the liquid albiglutide drug product 
compared to the lyophilized drug product is considered low based on the 
absence of substantive qualitative differences between formulations.A pre -exposure baseline serum sample will be taken and 
tested for pre -existing ADAs .
The development of anti -albiglutide antibodies will be 
assessed as part of this study.
Injection site reactions (ISRs) Albiglutide injections may cause ras h, erythema or itching and/or other reactions 
at the site of injection. 
In the Phase III program with the lyophilized drug product, most subjects with Subjects will be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via guidance for investigators (see 
2014N210004_02 CONFIDENTIA L
200952
96Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
ISRs did not test positive for anti -albiglutide antibodies. However, injection site 
reactions were repor ted more frequently among those who did test positive for 
anti-albiglutide antibodies (41 % of the ADA positive subjects reported one or 
more injection site reactions) than among those who were consistently antibody 
negative (14% of the antidrug antibody ne gative subjects reported one or more 
injection site reactions).  
Overall, for albiglutide, injection site reactions have not been associated with 
clinically significant sequelae; although they can be a tolerability issue and were 
the most common reason fo r withdrawal of study medication for subjects 
(approximately 2.0%) in the albiglutide group.
Differences between formulation characteristics (e.g. lower pH and larger 
volume for the 50 mg dose of the liquid formulation) may impact the injection 
site reacti on profile.Section 6 of the IB) and informed consent form for 
subjects.
Other adverse rea ctions
(e.g., pneumonia, atrial 
fibrillation/atrial flutter, appendicitis, 
and hypersensitivity reactions)In the Phase III program in T2DM, other possible albiglutide related adverse 
reactions were identified. These events occurred at a cumulative inciden ce <3% 
in studies up to [ADDRESS_484990] components (including yeast and human 
albumin) are excluded from the stu dy (See Section 
5.2).  
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.  
Thyroid C -cell tumors GLP-1 receptor agonists, including albiglutide increase serum calcitonin in 
rodents and oth er GLP -1 receptor agonists are associated with thyroid C -cell 
focal hyperplasia and C -cell tumors in rodents  It is unknown whether GLP -1 
receptor agonists are associated with thyroid C -cell tumors in humans, including 
medullary thyroid cancer (MTC). Subjects with a personal or family history of MTC or 
subjects with Multiple Endocrine Neoplasia syndrome type 
2 (MEN -2) are excluded from the study (See Section 5.2).
Subjects with treatment emergent thyroid nodules should 
be referred to a specialist for eval uation in accordance with 
local treatment guidelines.  Routine monitoring of serum 
calcitonin is not recommended.  However, if serum 
calcitonin is found to be elevated the subject should be 
referred to a specialist for further evaluation. If MTC or 
other thyroid C -cell neoplasia is diagnosed, study 
treatment will be discontinued (see Section 5.5).
2014N210004_02 CONFIDENTIA L
200952
97Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Other malignant neoplasms Theoretical concerns have been raised regarding use of incretin based 
therapi[INVESTIGATOR_387038] [Egan , 2014] and 
malignancy when used in combination with insulin based on hypotheses of 
biological plausibility [European Public Assessment Report, 2014], and 
hematological malignancies [FDA Summary Basis of Approval, 2014].Subjects with a history of cancer t hat has not been in full 
remission for at least 3 years before screening are 
excluded from the study (See Section 5.2).
Risk communication via guidance for investigators 
(see Section 6 of the IB) and informed consent form for 
subjects.  
Cardiovascular (C V) safety of 
antidiabetic therapyT2DM is associated with an elevated risk of CV disease. Global regulatory 
agencies require new antidiabetic therapi[INVESTIGATOR_387039]. 
In the Phase III registration program, an independent Clinical Endpoint 
Committee prospectively adjudicated blinded CV events. The final CV meta -
analysis showed no increased CV risk (MACE [major adverse cardiovascular 
event] + composed of CV death, myocardial inf arction [MI], stroke, and 
hospi[INVESTIGATOR_10929]) with albiglutide versus all comparators 
(MACE+ hazard ratio = 1.00; 95% CI: 0.68, 1.49).Subjects with clinically significant CV and/or 
cerebrovascular disease within 3 months before screening
will be excluded from the study. Further details are 
provided in Section 5.2
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.  
Hepatotoxicity Hepatotoxicity is an area of interest in dru g development.  Patients with T2DM 
are at increased risk for liver enzyme abnormalities and disease related liver 
conditions.  One subject treated with albiglutide in the Phase III clinical program 
developed probable drug induced liver injury with an asymp tomatic elevation in 
alanine amino transferase (ALT) and total bilirubin although the cases had some 
atypi[INVESTIGATOR_387019] . Routine liver safety laboratory evaluations will be 
conducted and specific withdrawal criteria for elevated l iver 
function tests have been defined (See Section 5.5.1).
Subject population with severe renal 
impairment (estimated glomerular 
filtration rate (eGFR) 
<30mL/min/1.73m2)Experience in T2DM subjects with severe renal impairment is limited (in the 
Phase II I programme a total of 19 subjects with eGFR <30 mL/min/1.73m2
received albiglutide). 
In a Phase III study of patients with varying degrees of renal impairment, in the 
albiglutide group, on -therapy GI AEs occurred with a higher incidence and 
higher event rate in subjects with moderate and severe renal impairment 
compared to those with mild renal impairment. GI events may lead to 
dehydration and worsen renal function. Subjects with an eGFR ≤30 mL/min/1.73 m2(calculated 
using the Modification of Diet in Renal Disease (MDRD) 
formula) are excluded from the study (see Section 5.2).
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.  
2014N210004_02 CONFIDENTIA L
200952
98Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Drug interactions Albiglutide causes a delay in gastric empty ing, and thereby [CONTACT_387068].
During the development program, drug interactions studies were conducted 
with digoxin, warfarin, oral contraceptives, and simvastatin which demonst rated 
no clinically relevant PK or PD effects. Investigators will be advised to take the effect of albiglutide 
on gastric emptying into account when prescribing 
concomitant medication.
Fetal & neonatal developmental 
toxicityStudies in animals have shown reproductive toxicity. The potential risk for 
humans is unknown.  Albiglutide administration during the major period of 
organogenesis in female mice resulted in embryofetal lethality, and bent/wavy 
ribs in the fetus at 50 mg/kg/day.  
Given that albigluti de is an albumin -based protein therapeutic, it is likely to be 
transferred to breast milk and may increase neonatal –cell mass.   
Decreased body weight in offspring was observed in mice treated with 
albiglutide during gestation and lactation.Subjects who are breastfeeding, pregnant or planning a 
pregnancy during the course of the study are excluded. 
Additionally, all females of child -bearing potential must be 
taking adequate contraception during the study and have a 
negative pregnancy test prior to entry. See Section 5.[ADDRESS_484991] the potential to accelerate sexual maturation 
in monkeys based on absolute testes weight and similar trends in prostate, 
seminal vesicle, epi [INVESTIGATOR_387040].Subjects under 18 years of age are excluded (see Section 
5.1).
Albiglutide matching placebo 
injectionsAlbiglutide placebo injections using the lyophilized DCC pen injector were 
associated with a clinically relevant rate of injection site reactions in the Phase 
III studies.
There is no experience with placebo injections using the liquid auto -injector, 
including volume and pH differences from the lyophilized product placebo.Subjects will be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via informed consent form for 
subjects.
Amended text:
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Pancreatitis Acute pancreatitis has been reported in association with albiglutide and other 
GLP-1 receptor agonists in clinical trials and during postmarketing experience.
Albiglutide has not been studied in subjects with a history of pancreatitis to Subjects with a history of acute or chronic pancreatitis are 
excluded from entering the study (See Section 5.2).
Subjects will be informed of the characteristic symptom of 
2014N210004_02 CONFIDENTIA L
200952
99Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
determine whether they are at increased risk for pancreatitis. pancreatitis: persistent severe abdominal pain. If 
pancreatitis is suspected, albiglutide should be promptly 
discontinued and if pancreatitis is confirmed, study 
treatment will not be restarted (see Section 5.5).
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Gastrointestinal (GI) events. Albiglutide has not been studied in subjects with severe GI disease, including 
severe gastroparesis. 
Use of albiglutide can be associated with GI side effects such as diarrhea,
nausea, and vomiting.Subjects with severe gastroparesis are excluded from 
entering the study (See Section 5.2).
Subjects with a history of significant GI surgery that in the 
opi[INVESTIGATOR_387041] (See Section 5.2).
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Hypoglycemia. Albiglutide’s mechanism of action is associated with a low intrinsic risk of 
significant hypoglycemia when used as monotherapy or in combination with 
agents such as metformin which also have low intrinsic risk for significant 
hypoglycemia . To reduce the risk of hypoglycemia when starting 
albiglutide all sub jects are required to have HbA1c 
≥7.0 at screening (see Section 5.1). 
Subjects are neither allowed to use insulin nor insulin 
secretagogues during the study. Except as part of 
hyperglycemia rescue (see Section 5.4)
Risk communication via guidance for inve stigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Immunogenicity 
(e.g., including anti- drug antibodies, 
clinical sequelae of antidrug 
antibodies, severe hypersensitivity 
reactions, and other potential Risk a ssessment of the albiglutide molecule predicted low immunogenic 
potential, which was substantiated for the commercial lyophilized DCC pen 
injector product in the registration program. Treatment -emergent anti- drug 
antibodies were detected in ~5 % subjects ov er studies of up to 3 years duration 
and were generally transient, of low titer, and not neutralizing.A pre -exposure baseline serum sample will be taken and 
tested for pre -existing ADAs .
The development of anti- albiglutide antibodies will be 
assessed as part of this study.
2014N210004_02 CONFIDENTIA L
200952
100Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
immune -related AEs). Subjects who tested positive for anti -albiglutide antibodies experienced a similar 
glycemic response (HbA1c and fasting plasma glucose) to those who did not 
test positive for antibodies. Other than injection site reactions (see below), the 
overall safety profile appeared similar among the subset of subjects who did 
and those who did not test positive for anti -albiglutide antibodies. 
Changes in the propens ity of the liquid product to form aggregates could have 
an impact on anti- drug antibody characteristics or immune related AEs.  
However, the likelihood of clinically important changes in anti -drug antibody 
characteristics or immune related AEs with the liq uid albiglutide drug product 
compared to the lyophilized drug product is considered low based on the 
absence of substantive qualitative differences between formulations.
Hypersensitivity Reactions Systemic allergic/hypersensitivity reactions are of potential concern with 
any injected protein and were reported rarely in the Phase III prog ram with 
lyophilized albiglutide. Data have not demonstrated an association of 
albiglutide with an increased incidence of anaphylaxis, angioedema, or 
urticaria. However, there was one non -serious hypersensitivity event (rash 
and itching associated with dys pnea upon rechallenge) that was 
consistent with a possible albiglutide -related systemic hypersensitivity 
reaction in a female subject who was anti -albiglutide antibody negative. 
See Section 5.[ADDRESS_484992] components (including yeast and human 
albumin) are excluded from the study (See Section 
5.2).  
Subjects will be informed of the symptoms of severe 
hypersensitivity or allergy and be advised to seek 
medical assistance immediately. 
Risk communicat ion via guidance for investigators 
(see Section 6 of the IB) and informed consent form for 
subjects.
Injection site reactions (ISRs) Albiglutide injections may cause rash, erythema or itching and/or other reactions 
at the site of injection. 
In the Phase III program with the lyophilized drug product, most subjects with 
ISRs did not test positive for anti- albiglutide antibodies. However, injection site 
reactions were reported more frequently among those who did test positive for 
anti-albiglutide antibodies (41%  of the ADA positive subjects reported one or 
more injection site reactions) than among those who were consistently antibody 
negative (14% of the antidrug antibody negative subjects reported one or more 
injection site reactions).  
Overall, for albiglu tide, injection site reactions have not been associated with Subjects will be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
The development of injection site reactions will be 
assessed as part of this study.
2014N210004_02 CONFIDENTIA L
200952
101Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
clinically significant sequelae; although they can be a tolerability issue and were 
the most common reason for withdrawal of study medication for subjects 
(approximately 2.0%) in the albiglutide group.
Differences between formulation characteristics (e.g. lower pH and larger 
volume for the 50 mg dose of the liquid formulation) may impact the injection 
site reaction profile.
Other adverse react ions
(e.g., pneumonia, atrial 
fibrillation/atrial flutter, appendicitis)In the Phase III program in T2DM, other possible albiglutide related adverse 
reactions were identified. These events occurred at a cumulative incidence <3% 
in studies up to 3 years in duration. These events were reported more frequently 
with albiglutide than comparators. Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.  
Thyroid C -cell tumors GLP-1 receptor agonists, including albiglutide increase serum calcitonin in 
rodents and other GLP -1 receptor agonists are associated with thyroid C -cell 
focal hyperplasia and C -cell tumors in rodents  It is unknown whether GLP -1 
receptor agonists are associated with thyroid C -cell tumors in humans, including 
medullary thyroid cancer (MTC). Subjects with a personal or family history of MTC or 
subjects with Multiple Endocrine Neoplasia syndrome type 
2 (MEN -2) are excluded from the study (See Section 5.2).
Subjects with treatment em ergent thyroid nodules should 
be referred to a specialist for evaluation in accordance with 
local treatment guidelines.  Routine monitoring of serum 
calcitonin is not recommended.  However, if serum 
calcitonin is found to be elevated the subject should be 
referred to a specialist for further evaluation. If MTC or 
other thyroid C -cell neoplasia is diagnosed, study 
treatment will be discontinued (see Section 5.5).
Other malignant neoplasms Theoretical concerns have been raised regarding use of incretin base d 
therapi[INVESTIGATOR_387038] [Egan, 2014] and 
malignancy when used in combination with insulin based on hypotheses of 
biological plausibility [European Public Assessment Report, 2014], and 
hematological malignancies [FDA Sum mary Basis of Approval, 2014].Relevant data on pancreatic cancer are summarized in 
IB Section 5.4.
Subjects with a history of cancer that has not been in full 
remission for at least 3 years before screening are 
excluded from the study (See Section 5.2).
Cardiovascular (CV) safety of 
antidiabetic therapyT2DM is associated with an elevated risk of CV disease. Global regulatory 
agencies require new antidiabetic therapi[INVESTIGATOR_387039]. 
In the Phase III registration program, an independent Clinical Endpoint 
Committee prospectively adjudicated blinded CV events. The final CV meta -Relevant data on cardiovascular events are 
summarized in IB Section 5.4.
Subjects with clinically significant CV and/or 
cerebrovascular disease within 3 months before screening 
will be excluded from the study. Further details are 
2014N210004_02 CONFIDENTIA L
200952
102Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
analysis showed no increased CV risk (MACE [major adverse cardiovascular 
event] + composed of CV deat h, myocardial infarction [MI], stroke, and 
hospi[INVESTIGATOR_10929]) with albiglutide versus all comparators 
(MACE+ hazard ratio = 1.00; 95% CI: 0.68, 1.49). See Section 5.4 of the IB.provided in Section 5.2
Risk communication via guidance for investigators (see 
Sectio n 6 of the IB) and informed consent form for 
subjects. 
Hepatotoxicity Hepatotoxicity is an area of interest in drug development.  Patients with T2DM 
are at increased risk for liver enzyme abnormalities and disease related liver 
conditions.  One subject t reated with albiglutide in the Phase III clinical program 
developed probable drug induced liver injury with an asymptomatic elevation in 
alanine amino transferase (ALT) and total bilirubin although the cases had some 
atypi[INVESTIGATOR_387042] . Routine liver safety laboratory evaluations will be 
conducted and specific withdrawal criteria for elevated liver 
function tests have been defined (See Section 5.5.1).
Subject population with severe renal 
impairment (estimated glomerular 
filtration rate (eGFR) 
<30mL/min/1.73m2)Experience in T2DM subjects with severe renal impairment is limited (in the 
Phase III programme a total of 19 subjects with eGFR <30 mL/min/1.73m2
received albiglutide). 
In a Phase III study of patients with varying degrees of renal impairment, in the 
albiglutide group, on -therapy GI AEs occurred with a higher incidence and 
higher event rate in subjects with moderate and severe renal impairment 
compared to those with mild renal impairment. GI events may lead to 
dehydration a nd worsen renal function. Subjects wit h an eGFR ≤30 mL/min/1.73 m2(calculated 
using the Modification of Diet in Renal Disease (MDRD) 
formula) are excluded from the study (see Section 5.2).
Risk communication via guidance for investigators (see 
Section 5.4 and Section 6 of the IB) and informed consent 
form for subjects.  
Drug interactions Albiglutide causes a delay in gastric emptying, and thereby [CONTACT_387068].
During the development program, drug interactions stud ies were conducted 
with digoxin, warfarin, oral contraceptives, and simvastatin which demonstrated 
no clinically relevant PK or PD effects. Investigators will be advised to take the effect of albiglutide 
on gastric emptying into account when prescribing 
concomitant medication.
Fetal & neonatal developmental 
toxicityStudies in animals have shown reproductive toxicity. The potential risk for 
humans is unknown.  Albiglutide administration during the major period of 
organogenesis in female mice resulted in e mbryofetal lethality, and bent/wavy 
ribs in the fetus at 50 mg/kg/day.  Offspring of mice dosed with 50 mg/kg/day 
during organogenesis had reduced pre- weaning body weight (which 
recovered after weaning), dehydration and coldness, and a delay in 
balanoprepu tial separation.Subjects who ar e breastfeeding, pregnant or planning a 
pregnancy during the course of the study are excluded. 
Additionally, all females of child -bearing potential must be 
taking adequate contraception during the study and have a 
negative pregnancy test prior to entry.  See Section 5.1 for 
further details.
2014N210004_02 CONFIDENTIA L
200952
103Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Given that albiglutide is an albumin -based protein therapeutic, it is likely to be 
transferred to breast milk. Decreased body weight in offspring was observed in 
mice treated with albiglutide during gestation and lactation.
Accelerated sexual maturation in 
juvenilesLong -acting GLP -1R agonists have the potential to accelerate sexual maturation 
in monkeys based on absolute testes weight and similar trends in prostate, 
seminal vesicle, epi[INVESTIGATOR_387040].Subjects under 18 years of age are excluded (see Section 
5.1).
Albiglutide matching placebo 
injectionsAlbiglutide placebo injections using the lyophilized DCC pen injector were 
associated with a clinically relevant rate of injection site reactions in the Phase 
III studies.
There is no experience with placebo injections using the liquid auto -injector, 
including volume and pH differences from the lyophilized product placebo.Subjects will be advised t hat when injecting in the same 
region, to use a different injection site each week.
Risk communication via informed consent form for 
subjects.
2014N210004_02 CONFIDENTIA L
200952
104Section 5.2, Exclusion Criteria 5
Original text:
5.History  of th yroid d ysfunction or an abnormal (i.e., outside the normal reference 
range) th yroid function test assessed b y thyroid stimulating hormone at screening.
Amended text:
5.Abnormal (i.e., outside the normal reference range) thy roid stimulating hormone 
(TSH) at screening.
Section 5.2, Exclusion Criteria 14, last sentence.
Original text:
14.eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula) at screening.
Note: As the use of metformin in subjects with vary ing degrees of renal function 
may differ from country  to country , use of metformin should be in accordance 
with the metformin produ ct label within the participating country .
Fasting triglyceride level >750 mg/dL at screening.
Amended text:
14.eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula) at screening.
Note: As the use of metformin in subjects with vary ing degrees of renal function 
may differ from country  to country , use of metformin should be in accordance 
with the metformin product label within the participating country .
Etc……
24.Fasting triglyceride level >750 mg/dL at screening.
Section 5.2, Exclusion Criteria 21
Original t ext:
21.A positive pre -study drug/alcohol screen.  
New text:
21. Positive urine alcohol/drug screen result at Screening, unless the subject is 
taking a medically approved medication for which a positive drug screen simply 
verifies the use of this medication
Section 5.2, Section 7, paragraph 4 and paragraph 5
New text:
2014N210004_02 CONFIDENTIA L
200952
105Study  visits between Baseline (Week 0) and End of treatment (Week 26) will have a visit 
window of ±3 day s and the follow -up visit (Week 34) will have a visit window of ±7 
days. If extraordinary  events that make it impossible for subjects to complete a 
visit/dosing within the visit window (e.g., holidays, personal emergencies), the 
investigator should contact [CONTACT_387058].  
If a subject misses a weekly  scheduled visit for receiving albiglutide treatments, the 
albiglutide treatments should be administered as soon as possible within [ADDRESS_484993]’s next regularly  scheduled visit.  If a subject misses [ADDRESS_484994] the medical monitor to discuss options for helpi[INVESTIGATOR_387028].  The medical monitor shall make a decision (on a case by  [CONTACT_17878]) on whether the subject should be withdrawn from the study .
2014N210004_02 CONFIDENTIA L
200952
106Section 7.1, Time and Events Table HbA1c
Original text:
ProcedureTreatment
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Week -2 0 1 2 3 4 5 6 7 8 9 10 11 12
HbA 1c 6,9 X X X X X
Amended text:
ProcedureTreatment
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Week -2 0 1 2 3 4 5 6 7 8 9 10 11 12
HbA 1c 6,9 X X X X X X
Section 7.1, Time and Events Table PK Sampling
Original text:
ProcedureTreatment
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Week -2 0 1 2 3 4 5 6 7 8 9 10 11 12
PK samples10
2014N210004_02 CONFIDENTIA L
200952
107ProcedureTreatment End of 
Treatment
13,14Follow -
up15
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Week 13 14 15 16 17 18 19 20 21 22 23 24 25 26 34
PK samples10 X X
Amended text:
ProcedureTreatment
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Week -2 0 1 2 3 4 5 6 7 8 9 10 11 12
PK samples10 X
ProcedureTreatment End of 
Treatment
13,14Follow -
up15
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Week 13 14 15 16 17 18 19 20 21 22 23 24 25 26 34
PK samples10 X
2014N210004_02 CONFIDENTIA L
200952
108Section 7.6.1, Blood Sample Collection
Original text:
Approximately 2 mL of blood wi ll be collected into 3mL di- potassium 
ethylenediaminetetraacetic acid (K 2-EDTA) tubes. The sample will be centrifuged in a 
refrigerated (4°C) centrifuge at [ADDRESS_484995] be frozen at -80°C within 60 minutes of collection.  
Amended text:
Blood samples will be collected and stored as detailed in the Study Reference Manual 
(SRM).
Section [IP_ADDRESS], Handl ing of Missing Data, Examination of Missing Data Patterns
Original text:
Examination of Missing Data Patterns
It is expected that the pattern of missing data will be similar in both treatment arms given 
that each treatment arm is using the same drug but di fferent formula. 
To examine the nature of missing data, cohorts of subjects will be defined based on the 
scheduled assessments (HbA1c change from baseline) that were completed at Weeks 1, 5, 
9, 13, 17, 21, and 26.
Subjects who have week 1 assessment only
Subjects who have assessments up to and including Week 5 only
Subjects who have assessments up to and including Week 9 only
Subjects who have assessments up to and including Week 13 only
Subjects who have assessments up to and including Week 17 only
Subjec ts who have assessments up to and including Week 21 only
Subjects who have assessments up to and including Week 26.
The number and percentage of subjects on each treatment in the 7 cohorts defined here 
will be tabulated. Graphical methods will be used to e xamine changes from baseline over 
time to assess the pattern of outcomes prior to withdrawal.
2014N210004_02 CONFIDENTIA L
200952
109Amended text:
Examination of Missing Data Patterns
It is expected that the pattern of missing data will be similar in both treatment arms given 
that each treatmen t arm is using the same drug but different formula. 
To examine the nature of missing data, cohorts of subjects will be defined based on the 
scheduled assessments (HbA1c change from baseline) that were completed at Weeks 1, 4, 
8, 12, 16, 20, and 26.
Subjec ts who have week 1 assessment only
Subjects who have assessments up to and including Week 4 only
Subjects who have assessments up to and including Week 8 only
Subjects who have assessments up to and including Week 12 only
Subjects who have assessments up to and including Week 16 only
Subjects who have assessments up to and including Week 20 only
Subjects who have assessments up to and including Week [ADDRESS_484996] is “lost to follow -up” or 
withdraws consent. 
2. Minor updates to benefit risk table 
3.Clarification in inclusion criteria that t hose subjects on a stable dose of metforim 
must be receiving metformin as monotherapy .
4.Exclusion criteria relating to use of dipeptidy l peptidase -IV inhibitors updated to 
include GL P [ADDRESS_484997] model 
with repeated measures (MMRM) in the intent -to-treat (ITT) population. MMRM will 
use all available data (including post -hyperglycemia rescue data). Non-inferiority  testing 
will be performed at a one- sided alpha of 0.025 and non -inferiorit y margin of 0.4.
Amended text:
HbA 1cchange from baseline at Week [ADDRESS_484998] model 
with repeated measures (MMRM) in the intent -to-treat (ITT) po pulation.  MMRM will 
use all available data, including post -hyperglycemia rescue data, and will include data 
from subj ects who discontinue treatment.  Im putation under the non -inferiority null 
hypothesis for missing data will be incorporated. Non-inferiori ty testing will be 
performed at a one -sided alpha of 0.[ADDRESS_484999] paragraph
Original text
The secondary  endpoint FPG change from baseline will be analyzed analogous to the 
primary en dpoint HbA 1cusing MMRM. Imputation for missing data will not be 
incorporated for the secondary endpoint FPG.
Amended text:
The secondary  endpoint FPG change from baseline at Week [ADDRESS_485000] discontinued study treatment (see Section 
5.5) or subjects who have completed the 26 week treatment period, but do not 
consent and/or are not eligible to participate in th e 26 week extension study (Study  
204682).
Amended text:
2.Follow -up visit only  for those subjects who discontinued investigational product (see 
Section 5.5), were withdrawn from the study, or who have completed the 26 week 
treatment period, but do not conse nt and/or are not eligible to participate in the 26 
week extension study  (Study  204682).
2014N210004_02 CONFIDENTIA L
200952
112Section 4.1, Overall Design, fourth bullet point 
Original text
During the screening period, subjects will provide written informed consent and 
undergo procedures to d etermine eligibility  for study  participation. (Time and Events 
Table Section 4).
Amended text:
During the screening period, subjects will provide written informed consent and 
undergo procedures to determine eligibility  for study  participation. Screening wi ll 
occur within 2 weeks of randomization. (Time and Events Table Section 7.1).
Section 4.[ADDRESS_485001] bullet point 
Original text
Subjects who complete the 26 week treatment period and meet all eligibility criteria 
may consent to participate in Study  204682, a 26 week extension study . 
Amended text:
Subjects, who completed the [ADDRESS_485002], and meet all eligibility  criteria may  consent to participate in 
Study  204682, a 26 week extension stu dy.
Section 4.2 , Treatment Arms and Duration , penultimate point 
Original text
Down -titration (dose reduction) of albiglutide from 50 mg to 30 mg is NOT 
permitted (see Section 4.4 ).  If a subject experiences tolerability  issues with the 
higher 50mg dose th en the subject may  be withdrawn from the study at the 
discretion of the investigator. 
Amended text:
Down -titration (dose reduction) of albiglutide from 50 mg to 30 mg is NOT 
permitted (see Section 4.4 ).  If a subject experiences tolerability  issues with t he 
higher 50mg dose then the subject may  discontinue investigational product (at the 
discretion of the investigator) and will be followed for safety and efficacy.
2014N210004_02 CONFIDENTIA L
200952
113Section 4.6.1, Table 2, Risk Assessment for Albiglutide
Original text:
Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Identified Risks
Pancreatitis Acute pancreatitis has been reported in association with 
albiglutide and other GLP -1 receptor agonists in clinical 
trials and during postmarketing experience.
Albiglutide has not been studied in subjects with a history 
of pancreatitis to determine whether they are at increased 
risk for pancreatitis. Subjects with a history of acute or chronic panc reatitis are 
excluded from entering the study (See Section 5.2).
Subjects will be informed of the characteristic symptom of 
pancreatitis: persistent severe abdominal pain. If 
pancreatitis is suspected, albiglutide should be promptly 
discontinued and if pan creatitis is confirmed, study 
treatment will not be restarted (see Section 5.5).
Risk communication via guidance for investigators (see 
Section 6 of the IB ) and informed consent form for 
subjects.
Gastrointestinal (GI) events. Albiglutide has not been stu died in subjects with severe GI 
disease, including severe gastroparesis. 
Use of albiglutide can be associated with GI side effects 
such as diarrhea, nausea, and vomiting.Subjects with severe gastroparesis are excluded from 
entering the study (See Section 5.2).
Subjects with a history of significant GI surgery that in the 
opi[INVESTIGATOR_387043] (See Section 5.2).
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
2014N210004_02 CONFIDENTIA L
200952
114Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Hypoglycemia. Albiglutide’s mechanism of action is associated with a low 
intrinsic risk of significant hypoglycemia when used as 
monotherapy or in combination with agents such as 
metformin which also have low intrinsic risk for significant 
hypoglycemia . To reduce the risk of hypo glycemia when starting 
albiglutide all subjects are required to have HbA1c ≥7.0 at 
screening (see Section 5.1). 
Subjects are neither allowed to use insulin nor insulin 
secretagogues during the study. Except as part of 
hyperglycemia rescue (see Section 5.4)
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
Immunogenicity 
(e.g., including anti- drug antibodies, clinical sequelae of 
antidrug antibodies, severe hypersensitivity reactions, and 
other potential immune -related AEs).Risk assessment of the albiglutide molecule predicted low 
immunogenic potential, which was substantiated for the 
commercial lyophilized DCC pen injector product in the 
registration program. Treatment -emergent anti -drug 
antibodies were detected in ~5 % subjects over studies of 
up to 3 years duration and were generally transient, of low 
titer, and not neutralizing.
Subjects who tested positive for anti -albiglutide antibodies 
experienced a similar glycemic response (HbA1c and
fasting plasma glucose) to those who did not test positive 
for antibodies. Other than injection site reactions (see 
below), the overall safety profile appeared similar among 
the subset of subjects who did and those who did not test 
positive for anti- albig lutide antibodies. 
Changes in the propensity of the liquid product to form 
aggregates could have an impact on anti -drug antibody 
characteristics or immune related AEs.  However, the 
likelihood of clinically important changes in anti -drug 
antibody characte ristics or immune related AEs with the 
liquid albiglutide drug product compared to the lyophilized 
drug product is considered low based on the absence of 
substantive qualitative differences between formulations.A pre -exposure baseline serum sample will be taken and 
tested for pre -existing ADAs .
The development of anti -albiglutide antibodies will be 
assessed as part of this study.
Hypersensitivity Reactions Systemic allergic/hypersensitivity reactions are of potential 
concern with any injected protein and were reported rarely Subjects with a known allergy to albiglutide or any product 
components (including yeast and human albumin) are 
2014N210004_02 CONFIDENTIA L
200952
115Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
in the Phase III program with lyophilized albiglutide. Data 
have not demonstrated an association of albiglutide with 
an increased incidence of anaphylaxis, angioedema, or 
urticaria. However, there was one non -serious 
hypersensitivity e vent (rash and itching associated with 
dyspnea upon rechallenge) that was consistent with a 
possible albiglutide -related systemic hypersensitivity 
reaction in a female subject who was anti -albiglutide 
antibody negative. See Section 5.4 of the IB.excluded from the study (See Section 5.2).  
Subjects will be informed of the symptoms of severe 
hypersensitivity or allergy and be advised to seek medica l 
assistance immediately. 
Risk communication via guidance for investigators (see 
Section 6 of the IB ) and informed consent form for 
subjects.
Injection site reactions (ISRs) Albiglutide injections may cause rash, erythema or itching 
and/or other reaction s at the site of injection. 
In the Phase III program with the lyophilized drug product, 
most subjects with ISRs did not test positive for anti -
albiglutide antibodies. However, injection site reactions 
were reported more frequently among those who did test
positive for anti- albiglutide antibodies (41% of the ADA 
positive subjects reported one or more injection site 
reactions) than among those who were consistently 
antibody negative (14% of the antidrug antibody negative 
subjects reported one or more injecti on site reactions).  
Overall, for albiglutide, injection site reactions have not 
been associated with clinically significant sequelae; 
although they can be a tolerability issue and were the most 
common reason for withdrawal of study medication for 
subject s (approximately 2.0 %) in the albiglutide group.
Differences between formulation characteristics (e.g. lower 
pH and larger volume for the 50 mg dose of the liquid 
formulation) may impact the injection site reaction profile.Subjects will be advised that wh en injecting in the same 
region, to use a different injection site each week.
Risk communication via guidance for investigators (see 
Section 6 of the IB) and informed consent form for 
subjects.
The development of injection site reactions will be 
assessed a s part of this study.
Other adverse reactions
(e.g., pneumonia, atrial fibrillation/atrial flutter, and 
appendicitis) In the Phase III program in T2DM, other possible 
albiglutide related adverse reactions were identified. These 
events occurred at a cumul ative incidence <3% in studies 
up to 3 years in duration. These events were reported 
more frequently with albiglutide than comparators. SeeRisk communication via guidance for investigators (see 
Section 6 of the IB) and informed cons ent form for 
subjects.
2014N210004_02 CONFIDENTIA L
200952
116Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Section 5.[ADDRESS_485003] (IP) (albiglutide [[COMPANY_004]716155])
Potential Risks
Thyroid C -cell tumors GLP-1 receptor agonists, including albiglutide increase 
serum calcitonin in rodents and other GLP -1 receptor 
agonists are associated with thyroid C -cell focal 
hyperplasia and C -cell tumors in rodents  It is unknown 
whether GLP -1 receptor agonists are associated with 
thyroid C -cell tumors in humans, including medullary 
thyroid cancer (MTC). Subjects with a personal or family history of MTC or 
subjects with Multiple Endocrine Neoplasia syndrome type 
2 (MEN -2) are excluded from the study (See Section 5.2 ).
Subjects with treatment emergent thyroid nodules should 
be referred to a specialist for evaluation in accordance with 
local treatment guide lines.  Routine monitoring of serum 
calcitonin is not recommended.  However, if serum 
calcitonin is found to be elevated the subject should be 
referred to a specialist for further evaluation. If MTC or 
other thyroid C -cell neoplasia is diagnosed, study 
treatment will be discontinued (see Section 5.5).
Other malignant neoplasms Theoretical concerns have been raised regarding use of 
incretin based therapi[INVESTIGATOR_387017] [ Egan , 2014] and malignancy when 
used in combination with insulin based on hypotheses of 
biological plausibility [ European Public Assessment 
Report , 2014], and hematological malignancies [ FDA
Summary Basis of Approval, 2014].Relevant data on pancreatic cancer are summarized in IB 
Section 5.4.
Subjects with a history of cancer that has not been in full 
remission for at least 3 years before screening are 
excluded from the study (See Section 5.2).
Cardiovascular (CV) safety of antidiabetic therapy T2DM is associated with an elevated risk of CV disease. 
Globa l regulatory agencies require new antidiabetic 
therapi[INVESTIGATOR_387018]. 
In the Phase III registration program, an independent 
Clinical Endpoint Committee prospectively adjudicated 
blinded CV events. The final CV meta -analysis showed no 
increased CV risk (MACE [major adverse cardiovascular 
event] + composed of CV death, myocardial infarction [MI], 
stroke, and hospi[INVESTIGATOR_10929]) with 
albiglutide versus all comp arators (MACE+ hazard ratio = Relevant data on cardiovascular events are summarized in 
IB Section 5.4.
Subjects with clinically significant CV and/or 
cerebrovascular disease within 3 months before scre ening 
will be excluded from the study. Further details are 
provided in Section 5.2.
Risk communication via guidance for investigators (IB 
Section 6) and informed consent form for subjects
2014N210004_02 CONFIDENTIA L
200952
117Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
1.00; 95% CI: 0.68, 1.49). See Section 5.[ADDRESS_485004] treated with albiglutide in the Phase III clinical 
program developed probable drug induced liver injury with 
an asymptomatic elevation in alanine amino transferase 
(ALT) and total bilirubin although the cases had some 
atypi[INVESTIGATOR_387019] . Routine liver safety laboratory evaluations will be 
conducted and specific withdrawal criteria for elevated liver 
function tests have been defined (See Section 5.5.4 ).
2014N210004_02 CONFIDENTIA L
200952
118Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Additional Considerations
Subject population with severe renal impairment 
(estimated glomerular filtration rate (eGFR) 
<30mL/min/1.73m2)Experience in T2DM subjects with severe renal impairment 
is limited (in the Phase III programme a total of 19 subjects 
with eGFR <30 mL/min/1.73m2received albiglutide). 
In a Phase III study of patients with varying degrees of 
renal impairment, in the albiglutide g roup, on -therapy GI 
AEs occurred with a higher incidence and higher event rate 
in subjects with moderate and severe renal impairment 
compared to those with mild renal impairment. GI events 
may lead to dehydration and worsen renal function. Subjects with a n eGFR ≤30 mL/min/1.73 m2(calculated 
using the Modification of Diet in Renal Disease (MDRD) 
formula) are excluded from the study (see Section 5.2).
Risk communication via guidance for investigators (see 
Section 5.4and Section 6 of the IB) and informed con sent 
form for subjects.  
Drug interactions Albiglutide causes a delay in gastric emptying, and thereby 
[CONTACT_387052].
During the development program, drug interactions 
studies were conducted with digoxin, warfarin, oral 
contraceptives, and simvastatin which demonstrated no 
clinically relevant PK or PD effects. Investigators will be advised to take the effect of albiglutide 
on gastric emptying into account when prescribing 
conco mitant medication.
Fetal & neonatal developmental toxicity Studies in animals have shown reproductive toxicity. The 
potential risk for humans is unknown.  Albiglutide 
administration during the major period of organogenesis in 
female mice resulted in embryofetal lethality, and 
bent/wavy ribs in the fetus at 50 mg/kg/day.  Offspring of 
mice dosed with 50 mg/kg/day during organogenesis had 
reduced pre -weaning body weight (which recovered after 
weaning), dehydration and coldness, and a delay in 
balanopreputial separation.
Given that albiglutide is an albumin -based protein 
therapeutic, it is likely to be transferred to breast milk. 
Decreased body weight in offspring was observed in mice 
treated with albiglutide during gestation and lactation.Subjects who are br eastfeeding, pregnant or planning a 
pregnancy during the course of the study are excluded. 
Additionally, all females of child -bearing potential must be 
taking adequate contraception during the study and have a 
negative pregnancy test prior to entry.  See S ection 5.1for 
further details.
2014N210004_02 CONFIDENTIA L
200952
119Potential Risk of Cl inical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Accelerated sexual maturation in juveniles Long -acting GLP -1R agonists have the potential to 
accelerate sexual maturation in monkeys based on 
absolute testes weight and similar trends in prostate, 
seminal vesicle, epi[INVESTIGATOR_387044].Subjects under 18 years of age are excluded (see Section 
5.1).
Study Procedures
Albiglutide matching placebo injections Albiglutide placebo injections using the lyophilized DCC 
pen injector were associ ated with a clinically relevant rate 
of injection site reactions in the Phase III studies.
There is no experience with placebo injections using the 
liquid auto -injector, including volume and pH differences 
from the lyophilized product placebo.Subjects wil l be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via informed consent form for 
subjects.
2014N210004_02 CONFIDENTIA L
200952
120Amended text
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Identified Risks
Pancreatitis Acute pancreatitis has been reported in association with 
albiglutide and other GLP -1 receptor agonists in clinical 
trials and during postmarketing experienc e.
Albiglutide has not been studied in subjects with a history 
of pancreatitis to determine whether they are at increased 
risk for pancreatitis. Subjects with a history of acute or chronic pancreatitis are 
excluded from entering the study (See Section 5.2).
Subjects will be informed of the characteristic symptom of 
pancreatitis: persistent severe abdominal pain. If 
pancreatitis is suspected, albiglutide should be promptly 
discontinued and if pancreatitis is confirmed, study 
treatment will not be restarted (see Section 5.5).
Risk communication via guidance for investigators (see 
albiglutide IB)and informed consent form for subjects.
Gastrointestinal (GI) events. Albiglutide has not been studied in subjects with severe GI 
disease, including severe gastropar esis. 
Use of albiglutide can be associated with GI side effects 
such as diarrhea, nausea, and vomiting.Subjects with severe gastroparesis are excluded from 
entering the study (See Section 5.2).
Subjects with a history of significant GI surgery that in th e 
opi[INVESTIGATOR_387043] (See Section 5.2).
Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for su bjects.
2014N210004_02 CONFIDENTIA L
200952
121Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
Hypoglycemia. Albiglutide’s mechanism of action is associated with a low 
intrinsic risk of significant hypoglycemia when used as 
monotherapy or in combination with agents such as 
metformin which also have low intrinsic risk for significant 
hypoglycemia. To reduce the risk of hypoglycemia when starting 
albiglutide all subjects are required to have HbA1c ≥7.0 at 
screening (see Section 5.1). 
Subjects are neither allowed to use insulin nor insulin 
secretagogues during the study except as part of 
hyperglycemi a rescue (see Section 5.4)
Risk communication via guidance for investigators (see 
the albiglutide IB) and informed consent form for 
subjects.
Immunogenicity 
(e.g., including anti- drug antibodies, clinical sequelae of 
antidrug antibodies, severe hypersens itivity reactions, and 
other potential immune -related AEs).Risk assessment of the albiglutide molecule predicted low 
immunogenic potential, which was substantiated for the 
commercial lyophilized DCC pen injector product in the 
registration program. Treatm ent-emergent anti -drug 
antibodies were detected in ~5 % subjects over studies of 
up to 3 years duration and were generally transient, of low 
titer, and not neutralizing.
Subjects who tested positive for anti -albiglutide antibodies 
experienced a similar glyc emic response (HbA1c and 
fasting plasma glucose) to those who did not test positive 
for antibodies. Other than injection site reactions (see 
below), the overall safety profile appeared similar among 
the subset of subjects who did and those who did not test
positive for anti- albiglutide antibodies. 
Changes in the propensity of the liquid product to form 
aggregates could have an impact on anti -drug antibody 
characteristics or immune related AEs.  However, the 
likelihood of clinically important changes in ant i-drug 
antibody characteristics or immune related AEs with the 
liquid albiglutide drug product compared to the lyophilized 
drug product is considered low based on the absence of 
substantive qualitative differences between formulations.A pre -exposure basel ine serum sample will be taken and 
tested for pre -existing ADAs .
The development of anti -albiglutide antibodies will be 
assessed as part of this study.
Risk communication via guidance for investigators 
(see albiglutide IB) and informed consent form for the
subject.
Hypersensitivity Reactions Systemic allergic/hypersensitivity reactions are of potential 
concern with any injected protein and were reported rarely Subjects with a known allergy to albiglutide or any product 
components (including yeast and human albumin) are 
2014N210004_02 CONFIDENTIA L
200952
122Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
in the Phase III program with lyophilized albiglutide. Data 
have not demonstrated an association of albiglutide with 
an increased incidence of anaphylaxis, angioedema, or 
urticaria. However, there was one non -serious 
hypersensitivity event (rash and itching associated with 
dyspnea upon rechallenge) that was consistent with a 
possible albiglutide -related systemic hypersensitivity 
reaction in a female subject who was anti -albiglutide 
antibody negative. See albiglutide IB.excluded from the study (See Section 5.2).  
Subjects will be informed of the symptoms of severe 
hypersensitivity or allergy and be advised to seek medical 
assistance immediately. 
Risk communication via guidance for investigators (see 
albiglutide IB) ) and informed consent form for subjects.
Injection site reactions (ISRs) Albiglutide injections may cause rash, erythema or itching 
and/or other reactions at the site of injection. 
In the Phase III program with the lyophilized drug product, 
most subjects with ISRs did not test positive for anti -
albiglutide antibodies. However, injection site reactions 
were reported more frequently among those who did test 
positive for anti- albiglutide antibodies (41% of the ADA 
positive subjects reported one or more injection site 
reactions) than among those who were consistently 
antibody negative (14% of the antidrug antibody negative 
subjects reported one or more injection site reactions).  
Overall, for albiglutide, injection site reactions have not 
been associated with clinically significant sequelae; 
although they can be a tolerability issue and were the most 
common reason for withdrawal of study medication for 
subjects (approximately 2.0 %) in the albiglutide group.
Differences between formulation characteristics (e.g. lower 
pH and larger volume for the 50 mg dose of the liquid 
formulation) may impact the injection site reaction profile.Subjects will be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for subjects.
The development of injection site reactions will be 
assessed as part of this study where the investigator or 
designee will administer both the albiglutide liquid 
drug product and the albiglutide l yophilized drug 
product .
Other adverse reactions
(e.g., pneumonia, atrial fibrillation/atrial flutter, and 
appendicitis) In the Phase III program in T2DM, other possible 
albiglutide related adverse reactions were identified. These 
events occurred at a cumulative incidence <3% in studies 
up to 3 years in duration. These events were reported 
more frequently with albiglutide than comparators. See Risk communication via guidance for investigators (see 
albiglutide IB) and informed consent form for subjects.
2014N210004_02 CONFIDENTIA L
200952
123Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
albiglutide IB .
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Potential Risks
Thyroid C -cell tumors GLP-1 receptor agonists, including albiglutide increase 
serum calcitonin in rodents and other GLP -1 receptor 
agonists are associated with thyroid C- cell focal 
hyperplasia and C -cell tumors in rodents  It is unknown 
whether GLP -1 receptor agonists are associated with 
thyroid C -cell tumors in humans, including medullary 
thyroid cancer (MTC). Subjects with a personal or family history of MTC or 
subjects with Multiple Endocrine Neoplasia syndrome type 
2 (MEN -2) are excluded from the study (See Section 5.2 ).
Subjects with treatment emergent thyroid nodules should 
be referred to a specialist for evaluation in accordance with 
local treatment guidelines.  R outine monitoring of serum 
calcitonin is not recommended.  However, if serum 
calcitonin is found to be elevated the subject should be 
referred to a specialist for further evaluation. If MTC or 
other thyroid C -cell neoplasia is diagnosed, study 
treatment wi ll be discontinued (see Section 5.5).
Other malignant neoplasms Theoretical concerns have been raised regarding use of 
incretin based therapi[INVESTIGATOR_387017] [ Egan , 2014] and malignancy when 
used in combination with insulin based on hypotheses of 
biological plausibility [ European Public Assessment 
Report , 2014], and hematological malignancies [ FDA
Summary Basis of Approval, 2014].Relevant data on pancreatic cancer are summarized in the 
albiglutide IB .
Subjects with a hi story of cancer that has not been in full 
remission for at least 3 years before screening are 
excluded from the study (See Section 5.2).A history of 
squamous cell or basal cell carcinoma of the skin or 
treated cervical intra -epi[INVESTIGATOR_28601] I or II i s 
allowed.
Cardiovascular (CV) safety of antidiabetic therapy T2DM is associated with an elevated risk of CV disease. 
Global regulatory agencies require new antidiabetic 
therapi[INVESTIGATOR_387018]. 
In the Phase III registration program, an independent 
Clinical Endpoint Committee prospectively adjudicated 
blinded CV events. The final CV meta -analysis showed no 
increased CV risk (MACE [major adverse cardiovascular 
event] + composed of CV death, myocardial infarction [MI], 
stroke, and hospi[INVESTIGATOR_10929]) with Relevant data on cardiovascular events are summ arized in 
IB Section 5.4.
Subjects with clinically significant CV and/or 
cerebrovascular disease within 3 months before screening 
will be excluded from the study. Further details are 
provided in Section 5.2
2014N210004_02 CONFIDENTIA L
200952
124Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
albiglutide versus all comparators (MACE+ hazard ratio = 
1.00; 95% CI: 0.68, 1.49). See Section 5.[ADDRESS_485005] treated with albiglutide in the Phase III clinical 
program developed probable drug induced liver injury wi th 
an asymptomatic elevation in alanine amino transferase 
(ALT) and total bilirubin although the cases had some 
atypi[INVESTIGATOR_387019] . Routine liver safety laboratory evaluations will be 
conducted and specific withdrawal criteria for elevated liver 
function tests have been defined (See Section 5.5.4 ).
2014N210004_02 CONFIDENTIA L
200952
125Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
Investigational Product (IP) (albiglutide [[COMPANY_004]716155])
Additional Considerations
Subject population with severe renal impairment 
(estimated glomerular filtration rate (eGFR) 
<30mL/min /1.73m2)Experience in T2DM subjects with severe renal impairment 
is limited (in the Phase III programme a total of 19 subjects 
with eGFR <30 mL/min/1.73m2received albiglutide). 
In a Phase III study of patients with varying degrees of 
renal impairment, i n the albiglutide group, on -therapy GI 
AEs occurred with a higher incidence and higher event rate 
in subjects with moderate and severe renal impairment 
compared to those with mild renal impairment. GI events 
may lead to dehydration and worsen renal functio n. Subjects with an eGFR ≤30 mL/min/1.73 m2(calculated 
using the Modification of Diet in Renal Disease (MDRD) 
formula) are excluded from the study (see Section 5.2).
Risk communication via guidance for investigators (see 
albiglutide IB )and informed consent form for subjects.  
Drug interactions Albiglutide causes a delay in gastric emptying, and thereby 
[CONTACT_387052].
During the development program, drug interactions 
studies were conducted with digoxin, warfarin, oral 
contraceptives, and simvastatin which demonstrated no 
clinically relevant PK or PD effects. Investigators will be advised to take the effect of albiglutide 
on gastric emptying into account when prescribing 
concomitan t medication.
Fetal & neonatal developmental toxicity Studies in animals have shown reproductive toxicity. The 
potential risk for humans is unknown.  Albiglutide 
administration during the major period of organogenesis in 
female mice resulted in embryofeta l lethality, and 
bent/wavy ribs in the fetus at 50 mg/kg/day.  Offspring of 
mice dosed with 50 mg/kg/day during organogenesis had 
reduced pre -weaning body weight (which recovered after 
weaning), dehydration and coldness, and a delay in 
balanopreputial sepa ration.
Given that albiglutide is an albumin -based protein 
therapeutic, it is likely to be transferred to breast milk. 
Decreased body weight in offspring was observed in mice 
treated with albiglutide during gestation and lactation.Subjects who are breastf eeding, pregnant or planning a 
pregnancy during the course of the study are excluded. 
Additionally, all females of child -bearing potential must be 
taking adequate contraception during the study and have a 
negative pregnancy test prior to entry.  See Sectio n 5.1for 
further details.
Risk communication via guidance for investigators 
(see albiglutide IB) and informed consent form for 
subjects.
2014N210004_02 CONFIDENTIA L
200952
126Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigat ion Strategy
Accelerated sexual maturation in juveniles Long -acting GLP -1R agonists have the potential to 
accelerate sexual matura tion in monkeys based on 
absolute testes weight and similar trends in prostate, 
seminal vesicle, epi[INVESTIGATOR_387020].Subjects under 18 years of age are excluded (see Section 
5.1).
Study Procedures
Albiglutide mat ching placebo injections Albiglutide placebo injections using the lyophilized DCC 
pen injector were associated with a clinically relevant rate 
of injection site reactions in the Phase III studies.
There is no experience with placebo injections using the 
liquid auto -injector, including volume and pH differences 
from the lyophilized product placebo.Subjects will be advised that when injecting in the same 
region, to use a different injection site each week.
Risk communication via informed consent form for 
subjects.
2014N210004_02 CONFIDENTIA L
200952
127Section 5.1 I nclusion Criteria 2
Original text
2. Historical diagnosis of T2DM (at least 3 months), experiencing inadequate gl ycemic 
control on current regimen of diet and exercise or on a stable maximal tolerated dose 
of metformin , maintained for approximately  8 weeks prior to screening.
Amended text:
2. Historical diagnosis of T2DM (at least 3 months), experiencing inadequate gl ycemic 
control on current regimen of diet and exercise or on a stable dose of metformin of 
at least 1500 mg or the documente d maximal tolerated dose if less than 1500 mg 
metformin (monotherapy), maintained for approximately  8 weeks prior to screening
Section 5.2 Exclusion Criteria 14
Original text
14.eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula) at screening.
Note: A s the use of metformin in subjects with varying degrees of renal function 
may differ from country to country, use of metformin should be in accordance 
with the metformin product label within the participating country.
Amended text:
25.eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula) at screening.
Note: The use of metformin in subjects with varying degrees of renal function   
should be in accordance with the metformin product label.
Section 5.2 Exclusion Criteria 18
Original text
18.Use of dipeptid yl peptidase -IV inhibitors within the 3 months before randomization.
Amended text:
18.Use of GLP 1 receptor agonists at any time . Use of dipeptidy l peptidase -IV 
inhibitors within the 3 months before randomization. Use of any other antidiabetic 
medications with the exception of metformin withi n 3 weeks before randomization.
Section 5.5 Withdrawal/Stoppi[INVESTIGATOR_387045]
5.5  Withdrawal/Stoppi[INVESTIGATOR_387046] . The reason for a subject not 
completing the stu dy will be recorded in the subject’s electronic case report form 
(eCRF).
2014N210004_02 CONFIDENTIA L
[ADDRESS_485006] and will be withdrawn from the study:
Any AE, which, in the opi[INVESTIGATOR_387023] a safety  concern
The following AEs will require withdrawal:
Confirmed pancreatitis, acute or chronic. 
Pancreatic cancer.
Confirmed MTC or other thy roid C -cell neoplasia.  
Liver chemistry  abnormalities exceeding the threshold criteria outlined in 
Section 5.5.4
QTc abnormalities exceeding the threshold criteria outlined in Section 5.5.5 .
Severe allergic/h ypersensitivity  reactions that are considered b y the 
investigator to be attributable to investig ational product or without a likely  
alternative aetiology .
eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula).
Subject becomes pregnant or intends to become pregnant during the stud y.
Need for chronic use of a prohibited concomitant medication (Se ction 6.10.2 )
Major protocol deviation (the investigator should discuss the protocol deviation with 
the medical monitor before withdrawing stud y medication)
Subject decision (reason to be documented in the eCRF, if specified b y the subject)
Investigator di scretion 
Study  closed/terminated or investigator site closed (where subject transfer to another 
site is not possible)
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993] -schedule the missed visit as soon 
as possible. 
The site must counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in 
the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or designee 
must make every  effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_485007]’s last known mailing address or 
local equivalent methods). These contact [CONTACT_244181]’s medical record. 
2014N210004_02 CONFIDENTIA L
200952
129Should the subject continue to be unreachable, only then will he/she be considered to 
have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
Subjects who are withdrawn or discontinue active participation in the study  will no 
longer receive the randomized study  treatment. Immediately  upon discontinuation from 
active participation in this study , these subjects shoul d complete the assessments as per 
the end of treatment clinic visit and return for the post- treatment follow -up clinic visit 8 
weeks later (Section 7.1). If a subject is unable or unwilling to return for the follow -up 
assessments, every  effort will be made to follow -up with the subject.
Withdrawn subjects will not be replaced. 
A subject may withdraw from study treatment at any time at his/her own request, or 
may be withdrawn at any time at the discretion of the investigator for safety, behavioral 
or admini strative reasons. If a subject withdraws from the study, he/she may  request 
destruction of an y samples taken, and the investigator must document this in the site 
study  records . 
Amended text:
5.5  Withdrawal/Stoppi[INVESTIGATOR_387046] . The reason for a subject 
discontinuing investigational product or withdrawing from the study will be recorded 
in the subject’s electronic case report form (eCRF). 
5.5.[ADDRESS_485008] at any time at his/her 
own request, or at the discretion of the investigator for safety or compliance reasons.  A 
subject must permanently discontinue investigational product for the pre -specified 
reasons below. 
Any AE, which, in the opi[INVESTIGATOR_387023] a safety  concern
The following AEs will require discontinuation from investigational product:
Confirmed pancreatitis, acute or chron ic. 
Pancreatic cancer.
Confirmed MTC or other thy roid C -cell neoplasia.  
Liver chemistry  abnormalities exceeding the threshold criteria outlined in 
Section 5.5.4
QTc abnormalities exceeding the threshold criteria outlined in Section 5.5.5 .
Severe allergi c/hypersensitivity  reactions that are considered b y the 
investigator to be attributable to investigational product or without a likely 
alternative aetiology .
2014N210004_02 CONFIDENTIA L
200952
130eGFR ≤30 mL /min/1.73 m2(calculated using the MDRD formula).
Subject becomes pregnant or intends to become pregnant during the stud y.
Need for chronic use of a prohibited concomitant medication (Section 6.10.2 )
Major protocol deviation (the investigator sh ould discuss the protocol deviation with 
the medical monitor before withdrawing stud y medication)
Subject decision (reason to be documented in the eCRF, if specified b y the subject)
Investigator discretion 
Study  closed/terminated or investigator site clos ed (where subject transfer to another 
site is not possible)
In all cases, the reasons for investigational product discontinuation and the date of the 
last dose will be recorded in the subject’s electronic case report form (eCRF) and the 
subject will contin ue in the study as described in [IP_ADDRESS].
[IP_ADDRESS]  Procedures for Subject Follo w-up Following Discontinuation of 
Investigational Product
Subjects will be educated on the importance of remaining in the study and attending all 
scheduled study visits. 
Subject s who permanently discontinue investigational product will be expected to 
attend clinic visits every 4 weeks through the End of Treatment visit, according to the 
study visit schedule, unless consent is actively withdrawn. Complete details are 
provided in t he Time and Events Table (Section 7.1).
If a subject is unable or unwilling to continue attending clinic visits in person, other 
subject follow -up options to collect subject information as detailed in the informed 
consent (e.g., telephone calls, letters, r eview of subjects medical records) should be 
pursued.
5.5.[ADDRESS_485009] who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as soon 
as possible. 
The site must counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in 
the study . 
In ca ses where the subject is deemed ‘lost to follow up’, the investigator or designee 
must make every  effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_485010]’s last known mailing address o r 
local equivalent methods). These contact [CONTACT_244181]’s medical record. 
2014N210004_02 CONFIDENTIA L
200952
131Should the subject continue to be unreachable, only then will he/she be considered to 
have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
5.5.[ADDRESS_485011]’s eCRF. If a subject withdraws from the stud y, he/she may  
request destruction of any  samples taken, and the investigator must document this in the 
site study  records . 
Subjects who are withdrawn or discontinue active participation in the study  will no 
longer receive the randomized study  treatment. Immediately  upon discontinuation from 
active participation in this study , these subjects should complete the assessments as per 
the end of treatment clinic visit and return for the post- treatment follow -up clinic visit 8 
weeks later (Section 7.1). If a subject is unable or unwilling to return for the follow-up 
assessments, every  effort will be made to follow -up with the subject.
Withdrawn subjects will not be replaced. 
Section 5.5.5  QTC Stoppi[INVESTIGATOR_2121], 3rdbullet.
Origin al text
A subject who meets the following criteria will be withdrawn from the study :
Amended text:
A subject who meets the following criteria will discontinue investigational product :
Section 6.3  Planned Dose A djustments, 2ndparagraph.
Original text
Dow n-titration (dose reduction) of albiglutide from 50 mg to 30 mg is NOT 
permitted (see Section 4.4 ).  If a subject experiences tolerability  issues with the 
higher 50mg dose then the subject may  be withdrawn from the study at the 
discretion of the investigator. 
Amended text:
Down -titration (dose reduction) of albiglutide from [ADDRESS_485012] (at the discretion of t he 
investigator) and be followed for safety and efficacy.
2014N210004_02 CONFIDENTIA L
[ADDRESS_485013] their 
metformin dose adjusted at the discretion of the investigator based on clinical need.
Amended text:
The use of metformin in subjects with varying degrees of renal function should be in 
accordance with the metformin product label. It is encouraged that a stable metformin 
dose is maintained during the stud y. However the metformin dose may be downtitrated 
based on clinical need at the discretion of the investigator. Up-titration of metformin is 
permitted for subjects who require hyperglycemic rescue and metformin is selected as 
the rescue medication.
Section 6.4   Blinding, penultimate bullet.
Original text
A subject will be withdrawn if the subject’s treatment code is unblinded by [CONTACT_253787]. The primary reason for discontinuation (the 
event or condition which led to the unblinding ) will be recorded in the eCRF.
Amended text:
If the subject’s treatment code is unblinded by [CONTACT_387069] 5.[ADDRESS_485014] sentence.
Original text
The medical monitor shall make a decision (on a case b y case basis) on whether the 
subject should be withdrawn from the study.
Amended tex t:
The medical monitor shall make a decision (on a case b y case basis) on whether the 
subject should continue to receive investigation product.
Table [ADDRESS_485015] discontinued study treatment (see Section 5.5)
or subjects who have completed the 26 week treatment period, but do not consent 
and/or are not eligible to participate in the 26 week extension study  (Study  204682).
Amended text:
2014N210004_02 CONFIDENTIA L
[ADDRESS_485016] (see 
Section 5.5 ), withdrawn from the study or  who have completed the 26 week 
treatment period, but do not consent and/or are not eligible to participate in the 26 
week extension study  (Study  204682).
Table [ADDRESS_485017] a treatment window as in the table> Subjects will not be considered 
out of compliance if visit windows extend because of extraordinary  events that make it 
impossible for  subjects to complete a visit within the above window (e.g., holiday s, 
vacations, personal emergencies). Determination of the maximum visit window deviation 
is at the discr etion of the medical monitor
2014N210004_02 CONFIDENTIA L
200952
134Table 4 Schedule of Assessments
Original text
ProcedureTreatment End of 
Treatment
13,14Follow -
up15
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Week 13 14 15 16 17 18 19 20 21 22 23 24 25 26 34
ProcedureTreatm ent End of 
Treatment
13,14Follow -
up15
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Week 13 14 15 16 17 18 19 20 21 22 23 24 25 26 34
Amended text
ProcedureTreatment
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Week -2 0 1 2 3 4 5 6 7 8 9 10 11 12
Visit Window -14d 0d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d
ProcedureTreatment End of 
Treatment1
3,14Follow -
up15
Visit 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Week 13 14 15 16 17 18 19 20 21 22 23 24 25 26 34
Visit Window ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±3d ±7d
2014N210004_02 CONFIDENTIA L
[ADDRESS_485018] 
ProcedureContinue Scheduled Clinic Visit 
(Weeks 4, 8, 12, 16, 20)4,5Week 26 
(Equivalent to End of Treatment 
Visit)Follow -up 
Week 34
Full (F) or brief (B) physical exam B F F
Weight X X X
12-lead ECG 1 X X
Vital Signs X X X
Clinical chemistry/h ematology samples2 X X X
HbA1c and FPG 3 X X X
Review AE/SAE, concomitant medication and hypoglycemia 
eventsX X X
1. 12- lead ECGs will be obtained before measurement of vital signs and collection of blood samples for laboratory testing. Vital signs measur ement will be taken before collection of 
blood samples. See Section 7.4.[ADDRESS_485019] attend the Week 26 visit.
5. Additional unscheduled visits will occur as medically necessary
2014N210004_02 CONFIDENTIA L
200952
136Section [IP_ADDRESS] AEs of Special I nterest, last paragraph
Original text
Subjects with drug h ypersensitivity  reactions that are not reasonabl y attributable to 
another cause or pancreatitis should be withdrawn from the study and should not be 
rechallenged with albiglutide (see Section 5.5for complete list of AEs of special interest 
requiring withdrawal).
Amended text:
Subjects with drug h ypersensitivity  reactions that are not reasonabl y attributable to 
another cause or pancreatitis should discontinue investigational product and should not 
be rechallenged with albiglutide (see Section 5.[ADDRESS_485020] requiring withdrawal).
Section 7.4.3. Phy sical Exams, penultimate sentence
Original text
Weight will be measured at each clinic visit.
Amended text:
Weight will be measured at the time points specified in the Time and Events Table 
Section 7.[ADDRESS_485021] be entered into the eCRF.
Amended text:
HbA 1cresults from a local laboratory must be entered into the eCRF.
Section 9.[ADDRESS_485022] model with 
repeated measures (MMRM) in the ITT Population. MMRM will use all available data 
(including post -hyperglycemia rescue data). Analysis excluding post -rescue HbA1c 
data will also be performed as supportive and is described in Section 9.4.[ADDRESS_485023]- baseline visits as 
dependent variables; treatment, region, age category , weight, background antidiabetic 
therap y, visi t week, and treatment- by-week interaction as fixed effects; baseline HbA1c 
as a continuous covariate; and subject as a random effect. Treatment effects estimates 
(and associated CI) of albiglutide liquid drug product will be evaluated within this 
MMRM mode l as least squares means contrasts relative to the lyophilized drug product. 
An unstructured covariance matrix will be used for the MMRM anal ysis, unless the 
model does not converge, in which case the covariance matrix will be decided upon 
model convergenc e status and the Akaike information criterion. 
The primary analysis will include all HbA1c values collected at scheduled visits up to 
Week 26. This will include values after hyperglycemia rescue. Missing data, in the 
context of the primary analysis at We ek 26, refer to those cases where the Week 26 
HbA1c value is not available or was not collected.
The primary endpoint HbA1c change from baseline at Week 26 may also be analyzed 
using the same MMRM model in the PP Population if needed as a supportive analys is.
Special attention will be paid to the handling of missing data in statistical analysis. 
Although, it is expected that the pattern of missing data will be similar in both 
treatment arms given that the treatment arms are the same drug but different 
formu lations. The method for the primary analysis, MMRM, assumes missing at 
random. The sensitivity of the results of analysis to the method of handling missing 
values will be investigated, especially if the number of missing values is substantial or 
if the characteristics of missing values differ between treatment groups. Further details 
of the sensitivity analysis, including imputation methods and assumptions about the 
missing data are described in Section [IP_ADDRESS].
9.4.[ADDRESS_485024] will be provided by 
[CONTACT_387049], and the associated 95% CI .
The overall general safety and tolerability  of albiglutide liquid drug product versus 
lyophilized drug product will be evaluated in tabular and/or graphical format and 
summarized descriptively. 
AEs and SAEs, phy sical examinations, clinical laboratory  evaluations, vital sign 
measurements, and [ADDRESS_485025] deviation (and/or standard error), minimum, and maximum. For categorical 
variables, the summaries will include frequencies and corresponding percentages. The 
exposure -adjusted incidence rate will also be calculated as the number of events in a 
given period divided b y the total person time on treatment of subjects at risk within the 
same period. The exposure- adjust ed incidence rate will be expressed as an annualized 
rate expected.  No inferential testing will be performed on the safety  variables. 
2014N210004_02 CONFIDENTIA L
200952
138Hypoglycemic events will be anal yzed separately from other AEs. All h ypogl ycemic 
events will be classified as severe, doc umented s ymptomatic, asymptomatic, probable 
symptomatic, and pseudohy poglycemia, as defined in Section 7.4.9 .
AEs will be coded using MedDRA. AEs will be summarized in various subsets, including 
on therap y AEs, related AEs, AEs leading to treatment discont inuation or withdrawal 
from study , SAEs, fatal AEs, etc. AEs will also be summarized by  [CONTACT_11196]  
(mild, moderate, and severe).
Anti- albiglutide antibod y results will be summarized by [CONTACT_1570]. In addition, the 
number and percentage of subje cts with positive results along with the antibody  titer 
values will be provided by [CONTACT_765]. 
The secondary endpoint FPG change from baseline at Week [ADDRESS_485026] -
baseline visits as dependent variables; treatment, visit week, and treatment- by-week 
interaction as fixed effects; baseline HbA1c or FPG as a continuous covariate; and 
subject as a random effect. Treatment effects estimates (and associated CI) of albiglutide 
liquid drug product will be evaluate d within this MMRM model as least squares means 
contrasts relative to the lyophilized drug product. An unstructured covariance matrix will 
be used for the MMRM analy sis, unless the model does not converge, in which case the 
covariance matrix will be decide d upon model convergence status and the Akaike 
information criterion. In addition, PD effect of albiglutide over time for both HbA1c and 
FPG change from baseline over time will be evaluated in tabular and/or graphical format 
and summarized descriptively .
PK trough plasma concentration data will be summarized by [CONTACT_3148]. No formal 
statistical analy ses will be conducted.
9.4.3  Other A nalyses
The anal yses of the primary  and secondary  efficacy  endpoints are described in Section 
9.4.1 and Section 9.4.2 . The details of an y further planned anal yses, including subgroup 
analysis and exploratory  endpoints, will be provided in the RAP.
9.4.4  Supportive A nalysis for Primary  Endpoint: Exclusion of Data after 
Rescue
It is not expected to have a substantial number of s ubjects who will require rescue and 
that number of subjects would be similar for both treatment arms.  However, to assess 
the impact of rescue, analysis of pre- rescue data will be performed. The model will be 
similar to the one used for the primary analysi s. Results of this analysis will 
supplement the primary analysis. In addition, exclusion of data after treatment 
2014N210004_02 CONFIDENTIA L
200952
139discontinuation may also be performed if a significant number of subjects discontinue 
study medication prior to Week 26.
9.4.5  Missing Data
[IP_ADDRESS]  Impact of Missing Data on Primary  Endpoint
Missing data, in the context of the primary analysis at Week 26, refer to those cases 
where the Week 26 HbA1c value is not available or was not collected. Missing data are 
not explicitly imputed in the prim ary MMRM analysis; although, there is an 
underlying assumption that data are missing at random. It is expected that the pattern 
of missing data will be similar in both treatment arms given that the treatment arms are 
the same drug but different formulas. A ll available scheduled post- baseline 
assessments up to endpoint are utilized and, via modeling of the within subject 
correlation structure, the derived treatment difference at Week 26 is adjusted to take 
into account missing data. The MMRM analysis (using saturated fixed effects and an 
unstructured variance -covariance matrix) is considered appropriate as the primary 
method of analysis, as it has been shown to give sensible answers to on -treatment 
questions in a range of practical situations [Siddiqui , 2009].
[IP_ADDRESS]  Extent of Missing Primary  Analysis Data
Missing data is expected to arise mainly from subjects missing complete visits. The 
amount of missing data for those baseline covariates included in the statistical anal ysis is 
expected to be none or at wo rst minimal. I f it should occur, that subject will effectivel y 
be lost to analy sis. Missing data for HbA1c between two non -missing visits will be 
considered missing at random (intermediate missing data).
In this stud y, subjects who withdraw from treatment will be withdrawn from the study . In 
the eCRF, the reason for treatment discontinuation and the reason for withdrawal from 
the study  are collected separatel y. Whenever the HbA1c value at Week 26 is missing 
(end of the stud y), the reason can be determined b ased on available data in these two 
locations.
The reason for missing data can be classified as follows: safety or  procedural 
(including withdrawal of consent).
[IP_ADDRESS]  Reasons for Withdra wal
Reasons for withdrawal are assumed to fall into three broad ca tegories:
Procedural (e.g., lost to follow- up, withdrew consent, protocol deviation, study 
closed/terminated, and investigator discretion): In this case, it is expected that 
an assumption of missing at random (MAR) is appropriate for imputation of 
HbA1c data after withdrawal.
Safety (e.g., AE, subject reached protocol- defined stoppi[INVESTIGATOR_3418]): It is 
expected that, in most cases, any change in safety related to these reasons for 
withdrawal would have been captured prior to the subject withdrawing from 
2014N210004_02 CONFIDENTIA L
200952
140the study. Missing HbA1c values after withdrawal due to safety concerns will 
be considered to possibly be missing not at random (MNAR).
Sensitivity analyses will be performed for data missing due to safety concerns.
[IP_ADDRESS]  Handling of Missing Data
The impact of missing data will be explored, as outlined below, for the ITT Analy sis 
Population only .
Examination of Missing Data Patterns
It is expected that the pattern of missing data will be similar in both treatment arms given 
that each treatment arm is using the same drug but different formula. 
To examine the nature of missing data, cohorts of subjects will be defined based on the 
scheduled assessments (HbA1c change from baseline) that were completed at Weeks 1, 
4, 8, 12, 16, 20, and 26.
Subjects who have week 1 assessment only
Subjects who have assessments up to and including Week 4 onl y
Subjects who have assessments up to and including Week 8 onl y
Subjects who have assessments up to and including Week 12 onl y
Subjects who have assessments up to and including Week 16 onl y
Subjects who have assessments up to and including Week 20 onl y
Subjects who have assessments up to and including Week 26.
The number and percentage of subjects on each treatment in the 7 cohorts defined here 
will be tabulated. Graphical method s will be used to examine changes from baseline over 
time to assess the pattern of outcomes prior to withdrawal.
Sensitivity Analyses –Multiple Imputation
Sensitivity analyses using multiple imputation methods will be conducted. Firstly, 
missing data betw een two non -missing time points will be considered missing at 
random.
The following multiple imputation methods are proposed based on whether data are 
missing at random or not missing at random:
All missing data assumed MAR: Imputation is based on means an d variances -
covariances from subjects in the same treatment group as the withdrawn subject 
and is comparable to MMRM. The main differences are that this approach uses 
separate covariance parameter estimation for each arm, and also separate 
regression param eters are estimated on baseline covariates within each arm. This 
more complex parameterization of the imputation model compared with the 
analysis model is valid. This approach will be used for all data missing post 
2014N210004_02 CONFIDENTIA L
[ADDRESS_485027] modification and the assumed rates of HbA1c increase after withdrawal, 
rather than anything to do with going from an MMRM approach to a multiple 
imputation approach. 
Missing due to the values of Week [ADDRESS_485028] (LMCF) that is MNAR: 
This approach assumes that a constant rate of increase in HbA1c change from 
baseline is experienced by [CONTACT_387070] y due to 
safety concerns. The MAR approach will be used for missing data due to 
procedural reasons. Sensitivity analyses using the LMCF approach will be 
performed using the following rates of HbA1c increase: 0%/month, 0.1%/month, 
and 0.2%/month to explore the potential impact as in a tippi[INVESTIGATOR_007]- point analysis. For 
each treatment group, these [ADDRESS_485029] multiple imputation rules.
Additional scenarios for sensitivity analysis may be added and described in the RAP.
Amended text:
9.[ADDRESS_485030] model with repeated measures (MMRM) in the ITT 
Population. MMRM will use all available data.  Imputation under the non -inferiority 
null hypothesis for missing data will be incorporated [ Koch , 2008]. Multiple imputation 
will be used to replace missing data of change from baseline of HbA1c at Week [ADDRESS_485031] -baseline 
visits as dependent variables; treatment, region, age category , weight, background 
antidiabetic therap y, visit week, and treatment -by-week interaction as fixed effects; 
baseline HbA1c as a continuous covariate; and subject as a random effect. Treatment 
effects estimates (and associated CI) of albiglutide liquid drug product will be evaluated 
within this MMR M model as least squares means contrasts relative to the lyophilized 
drug product. An unstructured covariance matrix will be used for the MMRM analy sis, 
unless the model does not converge, in which case the covariance matrix will be decided 
upon model conv ergence status and the Akaike information criterion. 
9.4.[ADDRESS_485032] will be provided by 
[CONTACT_387049], and the associated 95% CI .
The overall general safety and tolerability  of albiglutide liquid drug product versus 
lyophilized drug product will be evaluated in tabular and/or graphical format and 
summarized descriptively. 
AEs and SA Es, phy sical examinations, clinical laboratory  evaluations, vital sign 
measurements, and [ADDRESS_485033] deviation ( and/or standard error), minimum, and maximum. For categorical 
variables, the summaries will include frequencies and corresponding percentages. The 
exposure -adjusted incidence rate will also be calculated as the number of events in a 
given period divided b ythe total person time on treatment of subjects at risk within the 
same period. The exposure- adjusted incidence rate will be expressed as an annualized 
rate expected.  No inferential testing will be performed on the safety  variables. 
Hypoglycemic events wi ll be anal yzed separately from other AEs. All h ypogl ycemic 
events will be classified as severe, documented s ymptomatic, asymptomatic, probable 
symptomatic, and pseudohy poglycemia, as defined in Section 7.4.9 .
AEs will be coded using MedDRA. AEs will be sum marized in various subsets, including 
on therap y AEs, related AEs, AEs leading to treatment discontinuation or withdrawal 
from study , SAEs, fatal AEs, etc. AEs will also be summarized by  [CONTACT_11196]  
(mild, moderate, and severe).
2014N210004_02 CONFIDENTIA L
[ADDRESS_485034] -
baseline visits as dependent variables; treatment, visit week, and treatment -by-week 
interaction as fixed effects; baseline HbA1c or FPG as a continuous covariate; and 
subject as a random effect. Treatment effects est imates (and associated CI) of albiglutide 
liquid drug product will be evaluated within this MMRM model as least squares means 
contrasts relative to the lyophilized drug product. An unstructured covariance matrix will 
be used for the MMRM analy sis, unless t he model does not converge, in which case the 
covariance matrix will be decided upon model convergence status and the Akaike 
information criterion. In addition, PD effect of albiglutide over time for both HbA1c and 
FPG change from baseline over time will b e evaluated in tabular and/or graphical format 
and summarized descriptively .
PK trough plasma concentration data will be summarized by  [CONTACT_3148]. No formal 
statistical analy ses will be conducted.
9.4.3  Other A nalyses
The anal yses of the primary  and second ary efficacy  endpoints are described in Section 
9.4.1 and Section 9.4.2 . The details of an y further planned anal yses, including subgroup 
analysis and exploratory  endpoints, will be provided in the RAP.
9.4.4  Supportive A nalyses for Primary  Endpoint
The pr imary endpoint change from baseline in HbA1c at Week 26 will be analyzed 
using the same MMRM model as described in Section 9.4.1 but missing data are not 
explicitly imputed in this supportive analysis; although, there is an underlying 
assumption that data is missing at random. All available scheduled post -baseline 
assessments up to endpoint are utilized and, via modeling of the within subject 
correlation structure, the derived treatment difference at Week 26 is adjusted to take 
into account missing data. Th e MMRM analysis (using saturated fixed effects and an 
unstructured variance -covariance matrix) is considered appropriate as the supportive 
analyses, as it has been shown to give sensible answers to on- treatment questions in a 
range of practical situations [ Siddiqui , 2009].
Analysis excluding post -rescue and/or discontinuation from investigational product 
HbA1c data will also be performed as supportive.  It is not expected to have a 
substantial number of subjects who will require rescue and that number of su bjects 
would be similar for both treatment arms.  However, to assess the impact of rescue, 
analysis of pre -rescue data will be performed. The MMRM model will be similar to the 
2014N210004_02 CONFIDENTIA L
200952
144one used for the primary analysis.  Results of this analysis will supplement the primary 
analysis. No imputation will be conducted for this supportive analysis.
The primary endpoint HbA1c change from baseline at Week 26 may also be analyzed 
using MMRM model in the PP Population, if sample size is sufficient, imputation will 
not be con ducted for this supportive analysis. 
Further details of the supportive analyses will be provided in the RAP.
9.4.5  Missing Data
[IP_ADDRESS]  Impact of Missing Data on Primary  Endpoint
Missing data, in the context of the primary analysis at Week 26, refer to those cases 
where the Week [ADDRESS_485035] of missing data on the primary endpoint to be minimal. Imputation 
under the non -inferiority null hypothesis [ Koch , 2008] for all missing data for the 
primary analysis at Week 26 will be implemented.
[IP_ADDRESS]  Extent of M issing Primary  Analysis Data
Missing data is expected to arise mainly from subjects missing complete visits. The 
amount of missing data for those baseline covariates included in the statistical anal ysis is 
expected to be none or at worst minimal. If it should occur, that subject will effectivel y 
be lost to analy sis. Missing data for HbA1c between two non -missing visits will be 
considered missing at random (intermediate missing data).
In this stud y, subjects who withdraw from treatment will stay in the study . In the eCRF, 
the reason for treatment discontinuation and the reason for withdrawal from the study  are 
collected separatel y. Whenever the HbA1c value at Week 26 is missing (end of the 
study ), the reason can be determined based on available data in these two locations.
The reason for missing data can be classified as lost to follow -up or withdrawal of 
consent.
[IP_ADDRESS]  Reasons for Withdra wal
Reasons for withdrawal from the study are lost to follow- up or withdrawal consent.  All 
subjects who discontinuation from investigational product due to the reasons listed 
under Section 5.5 will remain in the study and efficacy and safety data will be 
collected.
2014N210004_02 CONFIDENTIA L
[PHONE_8080].4.5.[ADDRESS_485036] to follow -up or withdrawal consent,
cohorts of subjects will be defined based on the scheduled assessments (HbA1c change 
from baseline) that were completed at Weeks 1, 4, 8, 12, 16, 20, and 26.
Subjects who have week 1 assessment only
Subjects who have assessments up to and including Week 4 onl y
Subjects who have assessments up to and including Week 8 onl y
Subjects who have assessments up to and including Week 12 onl y
Subjects who have assessments up to and including Week 16 onl y
Subjects who have assessments up to and including Week 20 onl y
Subjects who have assessments up to and including Week 26.
The number and percentage of subjects on each treatment in the [ADDRESS_485037] and stayed in 
the study; exclusion of data after treatment discontinuation may also be performed if a 
significant number of subjects discontinue study medication prior to Week 26. On 
treatment data will be analyzed using MMRM model as described in Section 9.4.1.  
Week 26 observations off -treatment will be imputed under the non -infer iority null 
hypothesis [ Koch , 2008].
Sensitivity analyses using a different type of multiple imputation method will be 
conducted. Firstly, missing data between two non -missing time points will be 
considered missing at random (MAR). The analyses using the l ast mean carried 
forward (LMCF) approach will be performed using the following rates of HbA1c 
increase: 0%/month, 0.1%/month, and 0.2%/month to explore the potential impact as 
in a tippi[INVESTIGATOR_007]-point analysis. For each treatment group, these [ADDRESS_485038] multiple imputation 
rules.